ID,Title,Released,Class of Spike-Binding Protein,Protein 1,Protein 2,Protein 3,Protein 4,antibody_number,antigen_chain,heavy_chain,light_chain,spike_residues,in_ntd,in_rbd,in_ace2bind,multichain,missing_antigen_res
6W41,Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022,3/25/2020,Antibody,CR3022,,,,0,C,H,L,369;370;372;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;407;408;411;426;428;430;432;515;516;517;519,0,1,0,0,
6WPS,Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment,5/27/2020,Antibody,S309,,,,0,A,H,L,333;334;335;337;339;340;341;343;344;345;346;354;356;358;359;360;361;362;440;441;509,0,1,1,0,445;446;447;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490;491;502
6WPS,Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment,5/27/2020,Antibody,S309,,,,1,B,C,D,333;334;335;337;339;340;341;343;344;345;346;354;356;358;359;360;361;362;440;441;509,0,1,1,0,445;446;447;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490;491;502
6WPS,Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment,5/27/2020,Antibody,S309,,,,2,E,F,G,333;334;335;337;339;340;341;343;344;345;346;354;356;358;359;360;361;362;440;441;509,0,1,1,0,445;446;447;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490;491;502
6WPT,Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state),5/27/2020,Antibody,S309,,,,0,A,D,E,333;334;335;337;339;340;341;343;344;345;346;354;356;357;358;359;360;361;362;440;441;509,0,1,1,0,443;444;445;446;447;448;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;499;500;501;502;503
6WPT,Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state),5/27/2020,Antibody,S309,,,,1,C,H,L,333;334;335;337;339;340;341;343;344;345;346;354;356;358;359;360;361;362;440;441;444;509,0,1,1,0,445;446;447;455;456;457;458;459;460;461;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490
6XC2,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1,7/8/2020,Antibody,CC12.1,,,,0,A,H,L,403;405;406;408;415;416;417;419;420;421;443;448;453;455;456;458;459;460;473;475;476;477;484;486;487;489;490;493;495;496;498;500;501;502;503;504;505,0,1,1,0,446;447
6XC2,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1,7/8/2020,Antibody,CC12.1,,,,1,Z,X,Y,403;405;406;408;415;416;417;419;420;421;443;448;453;455;456;458;459;460;473;475;476;477;484;486;487;489;490;493;495;496;498;500;501;502;503;504;505,0,1,1,0,446;447
6XC3,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,7/8/2020,Antibody,CC12.1,CR3022,,,0,C,B,A,403;405;406;408;409;414;415;416;417;418;420;421;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;503;504;505,0,1,1,0,446;447
6XC3,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,7/8/2020,Antibody,CC12.1,CR3022,,,1,C,H,L,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;428;430;432;515;517;519,0,1,0,0,446;447
6XC4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3,7/8/2020,Antibody,CC12.3,,,,0,A,H,L,403;405;415;416;417;420;421;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
6XC4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3,7/8/2020,Antibody,CC12.3,,,,1,Z,X,Y,403;405;415;416;417;419;420;421;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
6XC7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,7/8/2020,Antibody,CC12.3,CR3022,,,0,A,C,D,403;405;415;416;417;420;421;455;456;457;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,446;447
6XC7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,7/8/2020,Antibody,CC12.3,CR3022,,,1,A,H,L,369;370;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;408;411;428;430;432;515;517;519,0,1,0,0,446;447
6XCM,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 1),7/1/2020,Antibody,C105,,,,0,B,N,S,403;404;405;406;408;415;417;420;421;453;455;456;457;458;459;460;473;474;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,519
6XCM,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 1),7/1/2020,Antibody,C105,,,,1,C,H,L,403;404;405;408;415;416;417;420;421;447;453;455;456;458;459;460;473;474;475;476;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,519
6XCN,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2),7/1/2020,Antibody,C105,,,,0,A,B,D,403;404;405;408;415;417;420;421;447;453;455;456;457;458;459;460;473;475;486;487;489;493;496;498;501;502;504;505,0,1,1,0,519
6XCN,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2),7/1/2020,Antibody,C105,,,,1,C,H,L,403;404;405;408;415;417;420;421;447;453;455;456;458;459;460;473;475;486;487;489;493;496;498;501;502;504;505,0,1,1,0,519
6XCN,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2),7/1/2020,Antibody,C105,,,,2,E,F,G,403;404;405;408;415;417;420;421;453;455;456;457;458;459;460;473;475;486;487;489;493;496;498;501;502;504;505,0,1,1,0,519
6XDG,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,6/24/2020,Antibody,REGN10933,REGN10987,,,0,E,B,D,403;406;417;420;421;453;455;456;473;475;476;477;478;484;485;486;487;489;490;493,0,1,1,0,
6XDG,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,6/24/2020,Antibody,REGN10933,REGN10987,,,1,E,C,A,345;346;439;440;441;443;444;445;446;447;448;449;450;499;500,0,1,1,0,
6XE1,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing antibody, CV30 Fab",7/1/2020,Antibody,CV30,,,,0,E,H,L,403;405;415;416;417;420;421;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
6XEY,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4,7/22/2020,Antibody,4-Feb,,,,0,A,H,L,449;452;453;455;456;470;483;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
6XEY,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4,7/22/2020,Antibody,4-Feb,,,,1,B,F,G,449;452;453;455;456;470;472;475;479;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
6XEY,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4,7/22/2020,Antibody,4-Feb,,,,2,C,J,K,447;449;452;453;455;456;470;472;473;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
6XKP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270,10/14/2020,Antibody,CV07-270,,,,0,A,H,L,346;348;349;351;442;444;446;447;448;449;450;451;452;470;483;484;485;490;492;493;494;498,0,1,1,0,
6XKP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270,10/14/2020,Antibody,CV07-270,,,,1,B,M,N,346;349;351;352;442;444;445;446;447;448;449;450;451;452;470;482;483;484;490;492;493;494;498,0,1,1,0,
6XKQ,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250,10/14/2020,Antibody,CV07-250,,,,0,A,H,L,403;417;447;449;453;455;456;475;476;477;478;484;486;487;489;490;493;494;496;498;501;505,0,1,1,0,357;358;359;360;361;362;363;364;365;366;371;372;373;374;383;384;385;386;387;388;389;390;391;392;393;394;395;396
6YLA,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab,4/15/2020,Antibody,CR3022,,,,0,A,B,C,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;411;426;428;430;432;515;516;517;518;519,0,1,0,0,446;447
6YLA,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab,4/15/2020,Antibody,CR3022,,,,1,E,H,L,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;430;432;515;516;517;518;519,0,1,0,0,
6YM0,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1),4/29/2020,Antibody,CR3022,,,,0,E,H,L,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;430;432;515;516;517;518;519,0,1,0,0,
6YOR,Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab,4/29/2020,Antibody,CR3022,,,,0,A,B,C,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;430;432;515;516;517;518;519,0,1,0,0,
6YOR,Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab,4/29/2020,Antibody,CR3022,,,,1,E,H,L,369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;430;432;515;516;517;518;519,0,1,0,0,
6Z2M,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",6/3/2020,"Antibody
Nanobody/Sybody",CR3022,H11-D4,,,0,A,B,C,369;370;372;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;408;428;430;432;515;517;518;528,0,1,0,0,
6ZDG,Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/29/2020,Antibody,EY6A,,,,0,A,B,C,365;369;377;378;379;380;381;382;383;384;385;386;388;389;390;392;412;413;427;428;429;430;517,0,1,0,0,
6ZDG,Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/29/2020,Antibody,EY6A,,,,1,D,F,G,365;369;377;378;379;380;381;382;383;384;385;386;388;389;390;392;412;413;427;428;429;430;517,0,1,0,0,
6ZDG,Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/29/2020,Antibody,EY6A,,,,2,E,H,L,365;369;377;378;379;380;381;382;383;384;385;386;388;389;390;392;412;413;427;428;429;430;517,0,1,0,0,
6ZDH,SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab,7/1/2020,Antibody,EY6A,,,,0,A,H,L,369;377;378;379;380;381;382;383;384;385;386;388;389;390;392;411;412;413;427;428;429;430;517;529,0,1,0,0,
6ZDH,SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab,7/1/2020,Antibody,EY6A,,,,1,B,D,F,369;377;378;379;380;381;382;383;384;385;386;388;389;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,
6ZDH,SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab,7/1/2020,Antibody,EY6A,,,,2,C,G,I,365;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517;529,0,1,0,0,
6ZER,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab,6/24/2020,Antibody,EY6A,,,,0,A,B,C,369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,
6ZER,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab,6/24/2020,Antibody,EY6A,,,,1,D,F,G,369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,
6ZER,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab,6/24/2020,Antibody,EY6A,,,,2,E,H,L,369;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
6ZFO,Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/8/2020,Antibody,EY6A,,,,0,A,B,C,365;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
6ZFO,Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/8/2020,Antibody,EY6A,,,,1,E,H,L,365;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7A5R,Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement),9/16/2020,Antibody,CR3022,,,,0,A,H,L,368;369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;429;430;515;516;517;518,0,1,0,0,535;536;537;538
7A5R,Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement),9/16/2020,Antibody,CR3022,,,,1,B,I,M,368;369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;412;426;428;430;515;516;517;518,0,1,0,0,535;536;537;538
7A5S,Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement),9/16/2020,Antibody,CR3022,,,,0,A,H,L,368;369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;426;428;429;430;515;516;517;518,0,1,0,0,
7A5S,Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement),9/16/2020,Antibody,CR3022,,,,1,B,I,M,368;369;370;374;376;377;378;379;380;381;382;383;384;385;386;390;392;407;408;411;412;426;428;429;430;515;516;517;518,0,1,0,0,
7AKD,Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment,5/19/2021,Antibody,47D11,,,,0,B,H,L,334;335;337;338;339;340;342;343;362;363;364;365;366;367;368;370;371;373;527;529,0,1,0,0,
7AKD,Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment,5/19/2021,Antibody,47D11,,,,1,C,D,E,334;335;336;337;338;339;340;342;343;356;362;363;364;365;367;368;370;527;529,0,1,0,0,
7B3O,Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab,12/16/2020,Antibody,STE90-C11,,,,0,E,H,L,403;405;406;408;409;415;416;417;420;421;447;449;453;455;456;457;458;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7BEH,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,Antibody,COVOX-316,,,,0,E,H,L,447;449;455;456;475;483;484;485;486;487;488;489;490;492;493;494;496,0,1,1,0,
7BEI,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,3/3/2021,Antibody,COVOX-150,,,,0,E,H,L,403;405;406;408;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7BEJ,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 1),3/3/2021,Antibody,COVOX-158,,,,0,E,H,L,403;405;406;408;409;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;486;487;489;493;495;496;498;501;502;503;504;505,0,1,1,0,
7BEK,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 2),3/3/2021,Antibody,COVOX-158,,,,0,E,H,L,403;405;406;408;409;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7BEL,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,Antibody,COVOX-88,COVOX-45,,,0,R,H,L,403;405;406;409;416;417;453;455;456;473;475;476;480;484;485;486;487;489;490;493;496;505,0,1,1,0,
7BEL,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,Antibody,COVOX-88,COVOX-45,,,1,R,A,B,337;348;352;353;354;355;356;357;359;360;394;396;424;426;428;462;463;464;465;466;468;514;516;518;519;520;521;523,0,1,1,0,
7BEL,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,Antibody,COVOX-88,COVOX-45,,,2,X,C,D,337;348;353;354;355;356;357;359;360;394;396;424;426;428;462;463;464;465;466;468;514;516;518;519;520;521;523,0,1,1,0,
7BEL,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,Antibody,COVOX-88,COVOX-45,,,3,X,E,F,403;405;406;409;416;417;453;455;456;473;475;476;478;480;484;485;486;487;489;490;493;496;505,0,1,1,0,
7BEM,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 scFv,3/3/2021,Antibody,COVOX-269,,,,0,E,H,L,403;405;406;408;409;415;416;417;418;419;420;421;447;449;453;455;456;458;459;460;473;474;475;476;477;478;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7BEN,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253,COVOX-75,,,0,C,G,I,346;440;441;444;445;446;447;448;449;450;452;455;484;490;492;493;494;496;499;500,0,1,1,0,387;388;389
7BEN,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253,COVOX-75,,,1,C,D,F,417;421;455;456;473;475;476;477;478;480;484;485;486;487;488;489;490;493,0,1,1,0,387;388;389
7BEN,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253,COVOX-75,,,2,E,H,L,417;421;453;455;456;458;473;475;476;477;478;479;484;485;486;487;488;489;490;493,0,1,1,0,385;386;387
7BEN,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253,COVOX-75,,,3,E,A,B,346;440;442;444;445;446;447;448;449;450;452;455;484;490;492;493;494;496;499;500,0,1,1,0,385;386;387
7BEO,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253H55L,COVOX-75,,,0,R,H,L,417;421;453;455;456;458;473;475;476;477;478;484;485;486;487;488;489;490;493,0,1,1,0,
7BEO,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253H55L,COVOX-75,,,1,R,A,B,346;440;442;444;445;446;447;448;449;450;452;455;484;490;492;493;494;496;499;500,0,1,1,0,
7BEO,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253H55L,COVOX-75,,,2,X,E,F,346;440;442;444;445;446;447;448;449;450;452;455;484;490;492;493;494;496;499,0,1,1,0,
7BEO,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,Antibody,COVOX-253H55L,COVOX-75,,,3,X,C,D,417;421;453;455;456;458;473;475;476;477;478;479;484;485;486;487;488;489;490;493,0,1,1,0,
7BEP,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,Antibody,COVOX-384,S309,,,0,C,G,I,334;335;337;339;340;341;343;344;345;346;354;356;358;361;440;441;444;509,0,1,1,0,
7BEP,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,Antibody,COVOX-384,S309,,,1,C,D,F,446;447;449;452;455;456;470;472;475;478;483;484;485;486;487;488;489;490;492;493;494,0,1,1,0,
7BEP,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,Antibody,COVOX-384,S309,,,2,E,A,B,446;447;449;452;455;456;470;472;475;478;483;484;485;486;488;489;490;492;493;494,0,1,1,0,
7BEP,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,Antibody,COVOX-384,S309,,,3,E,H,L,334;335;337;339;340;341;343;344;345;354;356;358;361;440;441;509,0,1,1,0,
7BNV,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300,11/17/2021,Antibody,ION-300,,,,0,A,H,L,353;354;355;357;396;398;426;427;428;457;458;459;461;462;463;464;465;466;467;468;469;482;514;516;518;520,0,1,1,0,
7BWJ,crystal structure of SARS-CoV-2 antibody with RBD,6/3/2020,Antibody,P2B-2F6,,,,0,E,H,L,351;444;445;446;447;448;449;450;452;470;472;483;484;485;488;490;492;493;494;496,0,1,1,0,
7BYR,BD23-Fab in complex with the S ectodomain trimer,6/10/2020,Antibody,BD23,,,,0,B,H,L,446;449;452;470;484;485;486;489;490;492;493;494;496,0,1,1,0,
7BZ5,Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody,5/13/2020,Antibody,B38,,,,0,A,H,L,403;405;406;409;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;484;486;487;489;490;493;495;496;498;500;501;502;504;505,0,1,1,0,519
7C01,Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD,5/27/2020,Antibody,CB6,,,,0,A,H,L,403;405;406;408;409;415;416;417;418;419;420;421;447;453;455;456;457;458;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7C01,Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD,5/27/2020,Antibody,CB6,,,,1,B,C,D,403;405;406;408;409;415;416;417;418;420;421;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7C2L,S protein of SARS-CoV-2 in complex bound with 4A8,7/1/2020,Antibody,4A8,,,,0,A,H,L,143;144;145;146;147;148;150;152;153;155;245;246;247;248;249;250;251;257;260,1,0,0,0,252;253;254;255
7C2L,S protein of SARS-CoV-2 in complex bound with 4A8,7/1/2020,Antibody,4A8,,,,1,B,I,M,143;144;145;146;147;148;150;152;153;155;245;246;247;248;249;250;251;257;260,1,0,0,0,252;253;254;255
7C2L,S protein of SARS-CoV-2 in complex bound with 4A8,7/1/2020,Antibody,4A8,,,,2,C,J,N,143;144;145;146;147;148;150;152;153;155;245;246;247;248;249;250;251;257;260,1,0,0,0,252;253;254;255
7CAC,SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab.,2/24/2021,Antibody,H014,,,,0,"A,B",E,D,369;372;373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;435;436;437;439;440;475;476;486;487;502;503;504;506;508,0,1,1,1,445;446
7CAH,The interface of H014 Fab binds to SARS-CoV-2 S,8/12/2020,Antibody,H014,,,,0,A,E,D,369;372;373;374;375;376;377;378;380;384;405;407;408;411;412;413;414;425;429;432;433;435;436;437;439;502;503;504;508,0,1,1,0,474;475;476;477;478;479;480;481;482;483;484;485;486;487;488
7CAI,SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab,9/23/2020,Antibody,H014,,,,0,A,E,D,369;372;373;374;375;376;377;378;379;380;383;384;386;404;405;407;408;411;412;413;414;427;435;436;437;439;503;504;506;508,0,1,1,0,445;446
7CAI,SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab,9/23/2020,Antibody,H014,,,,1,"B,C",G,F,369;372;373;374;375;376;377;378;380;384;404;405;407;408;411;412;413;414;435;436;437;439;440;476;486;487;502;503;504;506;508,0,1,1,1,445;446
7CAK,SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab,9/23/2020,Antibody,H014,,,,0,A,E,D,369;372;373;374;375;376;377;378;380;405;407;408;411;412;413;414;427;435;436;437;440;502;503;504;506;508,0,1,1,0,445;446
7CAK,SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab,9/23/2020,Antibody,H014,,,,1,B,G,F,369;372;373;375;376;377;378;380;404;405;407;408;411;412;413;414;433;437;503;504;506;508,0,1,1,0,445;446
7CAK,SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab,9/23/2020,Antibody,H014,,,,2,C,I,H,372;373;375;376;377;378;404;405;408;411;412;413;414;435;437;439;440;502;503;506;508,0,1,1,0,445;446
7CDI,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD,11/18/2020,Antibody,P2C-1F11,,,,0,E,H,L,403;405;415;416;417;419;420;421;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;502;504;505,0,1,1,0,517;518;519
7CDJ,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,11/18/2020,Antibody,P2C-1A3,,,,0,E,H,L,447;449;452;455;456;475;476;478;481;483;484;485;486;487;488;489;490;492;493;494;496,0,1,1,0,
7CH4,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab,9/16/2020,Antibody,BD-604,,,,0,R,H,L,403;405;408;415;416;417;420;421;447;449;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;503;505,0,1,1,0,517;518;519;520;521
7CH5,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab,9/16/2020,Antibody,BD-629,,,,0,R,H,L,403;405;415;416;417;420;421;453;455;456;458;460;473;474;475;476;477;478;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7CHB,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab,9/16/2020,Antibody,BD-236,,,,0,R,H,L,403;405;406;415;416;417;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;503;504;505,0,1,1,0,517;518;519;520;521
7CHC,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-629,BD-368-2,,,0,R,H,L,403;405;415;416;417;419;420;421;447;455;456;457;458;459;460;473;475;476;477;478;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7CHC,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-629,BD-368-2,,,1,R,A,B,349;447;449;450;452;470;472;479;480;481;482;483;484;485;488;490;492;494;496,0,1,1,0,
7CHE,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-236,BD-368-2,,,0,R,H,L,403;405;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;478;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,517;518;519;520;521
7CHE,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-236,BD-368-2,,,1,R,A,B,447;449;450;452;470;471;472;480;481;482;483;484;485;490;492;493;494;496,0,1,1,0,517;518;519;520;521
7CHF,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-604,BD-368-2,,,0,R,A,B,447;449;450;452;470;472;480;481;482;483;484;485;488;490;492;493;494;496,0,1,1,0,517;518;519;520;521
7CHF,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,9/16/2020,Antibody,BD-604,BD-368-2,,,1,R,H,L,403;405;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;503;504;505,0,1,1,0,517;518;519;520;521
7CHH,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs,9/16/2020,Antibody,BD-368-2,,,,0,A,D,E,446;447;449;450;452;470;472;478;480;481;482;483;484;485;486;488;490;492;494;496,0,1,1,0,329;330;331;332;333
7CHH,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs,9/16/2020,Antibody,BD-368-2,,,,1,B,G,H,447;449;450;452;470;472;478;481;482;483;484;485;486;488;490;492;494;496,0,1,1,0,517;518;519;520
7CHH,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs,9/16/2020,Antibody,BD-368-2,,,,2,C,J,K,349;351;447;449;450;452;470;472;478;479;480;481;482;483;484;485;486;488;490;492;494,0,1,1,0,518;519;520
7CHO,Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD,5/19/2021,Antibody,P5A-1D2,,,,0,A,B,C,403;404;405;415;417;420;421;453;455;456;457;458;459;460;473;474;475;476;477;486;487;489;493;496;501;502;504;505,0,1,1,0,
7CHO,Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD,5/19/2021,Antibody,P5A-1D2,,,,1,E,H,L,403;405;408;415;416;417;419;420;421;453;455;456;458;460;473;474;475;476;477;486;487;489;493;496;502;504;505,0,1,1,0,
7CHP,Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD,5/19/2021,Antibody,P5A-3C8,,,,0,E,H,L,403;405;406;408;409;415;416;417;420;421;447;449;453;455;456;457;458;460;473;475;476;477;486;487;489;493;494;496;498;501;502;504;505,0,1,1,0,368;369;370;371
7CHS,Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD,5/19/2021,Antibody,P22A-1D1,,,,0,E,H,L,403;405;406;409;415;416;417;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;501;502;503;504;505,0,1,1,0,517;518;519;520
7CJF,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab,11/11/2020,Antibody,P4A1,,,,0,C,A,B,403;405;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,
7CM4,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,1/20/2021,Antibody,CT-P59,,,,0,A,H,L,349;403;417;447;449;450;452;453;455;456;475;483;484;485;486;489;490;492;493;494;496;498;501;502;505,0,1,1,0,
7CWL,SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state,1/27/2021,Antibody,P17,,,,0,A,H,L,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,331;332;333;528;529
7CWL,SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state,1/27/2021,Antibody,P17,,,,1,B,G,J,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,332;333;334
7CWL,SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state,1/27/2021,Antibody,P17,,,,2,C,I,K,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,332;333;528;529
7CWM,Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state,12/16/2020,Antibody,P17,,,,0,A,H,L,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,330;331;332;333;379;380;381;382;383;384;385;386;387;388;522;523;524;525;526;527;528;529
7CWM,Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state,12/16/2020,Antibody,P17,,,,1,B,G,J,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,330;331;332;333;528;529;530
7CWM,Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state,12/16/2020,Antibody,P17,,,,2,C,I,K,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,331;332;333;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,0,A,G,F,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,331;332;333;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,1,A,O,M,369;370;371;372;373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;429;435;436;437;503;504;506;508,0,1,1,0,331;332;333;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,2,B,K,I,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,331;332;333;334;527;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,3,B,E,D,369;370;371;372;373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;429;435;436;437;503;504;506;508,0,1,1,0,331;332;333;334;527;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,4,C,H,N,369;370;371;372;373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;429;435;436;437;503;504;506;508,0,1,1,0,331;332;333;528;529;530
7CWN,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,Antibody,P17,H014,,,5,C,L,J,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,331;332;333;528;529;530
7CWO,SARS-CoV-2 spike protein RBD and P17 fab complex,12/16/2020,Antibody,P17,,,,0,A,H,L,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,0,O,N,K,16;144;145;146;147;150;152;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,1,O,I,H,373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;433;435;437;439;440;502;503;506;508,0,1,1,0,445;446
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,2,Q,E,D,369;372;373;374;375;376;377;378;380;404;405;407;408;411;412;413;414;427;433;435;436;437;440;502;503;504;506;508,0,1,1,0,445;446
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,3,Q,L,C,16;144;145;146;147;148;150;152;155;246;248;249;251;256,1,0,0,0,252;253;254;255
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,4,R,P,M,16;144;145;146;147;148;150;152;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7CWS,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,Antibody,FC05,H014,,,5,R,G,F,369;372;373;375;376;377;378;380;404;405;407;408;411;412;413;414;433;435;436;437;503;504;506;508,0,1,1,0,445;446
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,0,A,L,H,16;142;144;145;146;147;148;150;152;155;158;246;248;249;251;256,1,0,0,0,252;253;254;255
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,1,A,E,D,375;403;404;437;439;440;443;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,328;329;330;331;332;333;334;526;527;528;529;530;531
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,2,B,N,K,16;142;144;145;146;147;148;150;152;155;158;246;248;249;251;256,1,0,0,0,252;253;254;255
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,3,B,G,F,403;404;437;439;440;443;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,329;330;331;527;528;529;530
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,4,C,I,J,375;404;405;437;439;440;443;444;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,331;332;528;529
7CWT,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,Antibody,HB27,FC05,,,5,C,P,M,16;142;144;145;146;147;148;150;152;153;155;158;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,0,A,J,F,16;144;145;146;147;148;150;152;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,1,A,O,S,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,332;333;528
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,2,B,N,G,16;144;145;146;147;150;152;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,3,B,H,L,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,333;528
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,4,C,P,I,16;144;145;146;147;148;150;152;155;246;248;249;251;256,1,0,0,0,252;253;254;255
7CWU,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,Antibody,P17,FC05,,,5,C,M,R,351;447;449;452;455;456;470;471;472;478;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,329;330;331;332;333;528;529;530
7CYH,Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27,6/9/2021,Antibody,HB27,,,,0,A,E,D,375;403;405;437;439;440;443;444;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,
7CYP,Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27,6/9/2021,Antibody,HB27,,,,0,A,E,D,375;404;437;439;440;443;444;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506;508,0,1,1,0,
7CYP,Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27,6/9/2021,Antibody,HB27,,,,1,B,G,F,375;403;404;437;439;440;443;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506;508,0,1,1,0,
7CYP,Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27,6/9/2021,Antibody,HB27,,,,2,C,I,H,375;403;404;437;439;440;443;445;446;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,
7CYV,"Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SARS-CoV-2 Spike receptor-binding domain (RBD)",9/15/2021,Antibody,FD20,,,,0,B,H,h,348;353;354;355;356;357;396;462;463;464;465;466;468,0,1,1,0,345
7CZP,S protein of SARS-CoV-2 in complex bound with P2B-1A1,3/10/2021,Antibody,P2B-1A1,,,,0,A,H,L,403;405;406;408;409;416;417;420;447;449;453;455;456;475;476;487;489;493;494;495;496;498;500;501;502;504;505,0,1,1,0,
7CZP,S protein of SARS-CoV-2 in complex bound with P2B-1A1,3/10/2021,Antibody,P2B-1A1,,,,1,C,J,N,403;405;406;408;409;416;417;420;447;449;453;455;456;475;476;487;489;493;494;495;496;498;500;501;502;504;505,0,1,1,0,
7CZQ,S protein of SARS-CoV-2 in complex bound with P2B-1A10,3/10/2021,Antibody,P2B-1A10,,,,0,A,H,K,403;405;406;408;409;415;416;417;418;420;421;447;449;452;455;456;458;460;473;475;476;477;478;486;487;489;493;494;495;496;498;500;501;502;503;504;505,0,1,1,0,
7CZQ,S protein of SARS-CoV-2 in complex bound with P2B-1A10,3/10/2021,Antibody,P2B-1A10,,,,1,C,J,N,403;405;406;408;409;415;416;417;418;420;421;447;449;452;455;456;458;460;473;475;476;477;478;486;487;489;493;494;495;496;498;500;501;502;503;504;505,0,1,1,0,
7CZR,S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B,3/10/2021,Antibody,P5A-1B8_2B,,,,0,A,H,K,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7CZR,S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B,3/10/2021,Antibody,P5A-1B8_2B,,,,1,C,J,N,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7CZS,S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B,3/10/2021,Antibody,P5A-1B8_3B,,,,0,A,H,K,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7CZS,S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B,3/10/2021,Antibody,P5A-1B8_3B,,,,1,B,I,M,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7CZS,S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B,3/10/2021,Antibody,P5A-1B8_3B,,,,2,C,J,N,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7CZT,S protein of SARS-CoV-2 in complex bound with P5A-2G9,3/10/2021,Antibody,P5A-2G9,,,,0,A,H,L,403;405;406;408;409;414;415;416;417;419;420;421;445;446;447;449;453;455;456;473;475;476;477;484;486;487;489;490;493;494;495;496;497;498;500;501;502;504;505,0,1,1,0,
7CZT,S protein of SARS-CoV-2 in complex bound with P5A-2G9,3/10/2021,Antibody,P5A-2G9,,,,1,C,I,M,403;405;406;408;409;414;415;416;417;419;420;421;445;446;447;449;453;455;456;473;475;476;477;484;486;487;489;490;493;494;495;496;497;498;500;501;502;504;505,0,1,1,0,
7CZU,S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B,3/10/2021,Antibody,P5A-1B6_2B,,,,0,A,H,K,403;405;408;409;415;416;417;420;421;447;449;453;455;456;475;484;486;487;489;493;494;495;496;498;501;502;504;505,0,1,1,0,
7CZU,S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B,3/10/2021,Antibody,P5A-1B6_2B,,,,1,C,J,N,403;405;408;409;415;416;417;420;421;447;449;453;455;456;475;484;486;487;489;493;494;495;496;498;501;502;504;505,0,1,1,0,
7CZV,S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B,3/10/2021,Antibody,P5A-1B6_3B,,,,0,A,H,K,403;405;408;409;415;416;417;420;421;447;449;453;455;456;475;484;486;487;489;493;494;495;496;498;501;502;504;505,0,1,1,0,
7CZV,S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B,3/10/2021,Antibody,P5A-1B6_3B,,,,1,B,I,M,403;405;408;409;415;416;417;420;421;447;449;453;455;456;475;484;486;487;489;493;494;495;496;498;501;502;504;505,0,1,1,0,
7CZV,S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B,3/10/2021,Antibody,P5A-1B6_3B,,,,2,C,J,N,403;405;408;409;415;416;417;420;421;447;449;453;455;456;475;484;486;487;489;493;494;495;496;498;501;502;504;505,0,1,1,0,
7CZW,S protein of SARS-CoV-2 in complex bound with P5A-2G7,3/10/2021,Antibody,P5A-2G7,,,,0,A,H,L,403;417;447;449;450;452;453;455;456;475;483;484;485;486;487;489;490;492;493;494;496;502;505,0,1,1,0,
7CZW,S protein of SARS-CoV-2 in complex bound with P5A-2G7,3/10/2021,Antibody,P5A-2G7,,,,1,C,J,N,403;417;447;449;450;452;453;455;456;475;483;484;485;486;487;489;490;492;493;494;496;502;505,0,1,1,0,
7CZX,S protein of SARS-CoV-2 in complex bound with P5A-1B9,3/10/2021,Antibody,P5A-1B9,,,,0,A,H,K,446;447;449;452;455;456;470;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
7CZX,S protein of SARS-CoV-2 in complex bound with P5A-1B9,3/10/2021,Antibody,P5A-1B9,,,,1,B,I,M,446;447;449;452;455;456;470;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
7CZX,S protein of SARS-CoV-2 in complex bound with P5A-1B9,3/10/2021,Antibody,P5A-1B9,,,,2,C,J,N,446;447;449;452;455;456;470;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
7CZY,S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B,3/10/2021,Antibody,P5A-2F11_2B,,,,0,A,H,K,420;421;453;455;456;458;473;474;475;476;477;478;483;484;486;487;489;490;493;496,0,1,1,0,
7CZY,S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B,3/10/2021,Antibody,P5A-2F11_2B,,,,1,C,J,N,420;421;453;455;456;458;473;474;475;476;477;478;483;484;486;487;489;490;493;496,0,1,1,0,
7CZZ,S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B,3/10/2021,Antibody,P5A-2F11_3B,,,,0,A,H,K,420;421;453;455;456;458;473;474;475;476;477;478;483;484;486;487;489;490;493;496,0,1,1,0,
7CZZ,S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B,3/10/2021,Antibody,P5A-2F11_3B,,,,1,B,I,M,420;421;453;455;456;458;473;474;475;476;477;478;483;484;486;487;489;490;493;496,0,1,1,0,
7CZZ,S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B,3/10/2021,Antibody,P5A-2F11_3B,,,,2,C,J,N,420;421;453;455;456;458;473;474;475;476;477;478;483;484;486;487;489;490;493;496,0,1,1,0,
7D00,S protein of SARS-CoV-2 in complex bound with FabP5A-1B8,3/10/2021,Antibody,FabP5A-1B8,,,,0,A,H,K,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7D00,S protein of SARS-CoV-2 in complex bound with FabP5A-1B8,3/10/2021,Antibody,FabP5A-1B8,,,,1,C,J,N,403;405;415;416;417;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7D03,S protein of SARS-CoV-2 in complex bound with FabP5A-2G7,3/10/2021,Antibody,FabP5A-2G7,,,,0,A,H,L,403;417;447;449;450;452;453;455;456;475;483;484;485;486;487;489;490;492;493;494;496;502;505,0,1,1,0,
7D0B,S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B,3/10/2021,Antibody,P5A-3C12_1B,,,,0,A,H,L,417;455;456;475;483;484;485;486;489;490;493,0,1,1,0,
7D0C,S protein of SARS-CoV-2 in complex bound with P5A-3A1,3/10/2021,Antibody,P5A-3A1,,,,0,A,H,L,405;415;417;420;421;447;455;456;458;460;473;474;475;476;477;486;487;489;493;496;498;501;502;505,0,1,1,0,
7D0C,S protein of SARS-CoV-2 in complex bound with P5A-3A1,3/10/2021,Antibody,P5A-3A1,,,,1,C,G,F,405;415;417;420;421;447;455;456;458;460;473;474;475;476;477;486;487;489;493;496;498;501;502;505,0,1,1,0,
7D0D,S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B,3/10/2021,Antibody,P5A-3C12_2B,,,,0,A,H,L,417;455;456;475;483;484;485;486;489;490;493,0,1,1,0,
7D0D,S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B,3/10/2021,Antibody,P5A-3C12_2B,,,,1,B,G,F,417;455;456;475;483;484;485;486;489;490;493,0,1,1,0,
7D4G,A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2,4/7/2021,Antibody,FC05,,,,0,B,N,G,16;144;145;146;147;148;150;152;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7D6I,A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2,10/13/2021,Antibody,GH12,,,,0,A,B,C,369;370;372;374;375;376;377;378;379;380;383;384;385;407;408;411;435;437,0,1,0,0,
7DCC,"S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab",12/2/2020,Antibody,3C1,,,,0,E,D,H,369;374;375;376;377;378;379;380;381;382;383;384;386;403;405;407;408;411;414;416;433;435;502;503;504;505,0,1,1,0,
7DCC,"S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab",12/2/2020,Antibody,3C1,,,,1,I,B,M,369;370;372;374;375;376;377;378;379;380;383;384;385;386;403;404;405;408;411;414;433;435;437;439;496;501;502;503;504;505;506;508,0,1,1,0,
7DCC,"S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab",12/2/2020,Antibody,3C1,,,,2,K,A,F,369;372;374;375;376;377;378;379;380;382;383;384;386;403;405;406;407;408;410;411;414;417;433;435;496;501;502;503;504;505,0,1,1,0,
7DCX,"S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.",12/2/2020,Antibody,3C1,,,,0,C,A,F,369;370;372;375;376;377;378;379;380;383;384;385;404;405;407;408;411;432;433;435;437;439;447;496;498;500;501;502;503;504;505;506;508,0,1,1,0,
7DCX,"S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.",12/2/2020,Antibody,3C1,,,,1,D,B,G,342;365;366;367;368;369;370;371;372;373;374;375;377;379;384;385;387;388;432;434;436;437;440;441;513;527,0,1,1,0,
7DCX,"S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.",12/2/2020,Antibody,3C1,,,,2,K,E,H,369;373;375;376;378;379;380;381;382;383;384;385;386;403;404;405;407;408;409;411;412;413;414;415;417;420;421;427;428;430;433;435;437;455;456;473;475;489;493;502;503;504;505,0,1,1,0,
7DD2,"S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.",12/2/2020,Antibody,3C1,,,,0,C,A,B,369;370;371;372;374;375;376;377;378;379;380;383;384;387;404;405;407;408;432;433;435;437;501;502;503;504;505;506;508,0,1,1,0,
7DD2,"S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.",12/2/2020,Antibody,3C1,,,,1,"D,K",E,H,365;369;370;376;377;378;379;380;384;403;405;406;407;408;410;411;413;414;416;417;432;433;435;478;479;486;487;496;501;502;503;504;505;510,0,1,1,1,
7DD8,"S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab",12/2/2020,Antibody,3C1,,,,0,"C,D",A,B,369;370;372;374;375;376;377;378;379;380;383;384;403;405;407;408;432;477;478;487;496;498;501;502;503;504;505;508,0,1,1,1,
7DEO,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,Antibody,PR1077,,,,0,B,A,a,403;405;417;447;449;450;452;453;455;456;473;475;484;486;487;489;490;493;494;496;498;501;505,0,1,1,0,
7DEO,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,Antibody,PR1077,,,,1,D,C,c,403;405;417;447;449;452;453;455;456;473;475;484;486;487;489;490;493;494;496;498;501;505,0,1,1,0,
7DET,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,Antibody,PR961,,,,0,A,B,b,345;346;373;437;439;440;441;442;443;444;445;448;450;451;497;499;500;507,0,1,1,0,
7DET,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,Antibody,PR961,,,,1,C,D,d,345;346;373;437;439;440;441;442;443;444;445;448;450;451;497;499;500;507,0,1,1,0,
7DEU,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,Antibody,PR953,,,,0,A,B,b,456;458;474;475;476;477;486;487;489,0,1,1,0,
7DJZ,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,6/9/2021,Antibody,MW01,,,,0,C,A,B,349;351;417;444;446;447;449;450;452;453;455;456;470;473;475;484;485;486;487;489;490;492;493;494;496,0,1,1,0,
7DK0,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab,6/9/2021,Antibody,MW05,,,,0,C,A,B,349;351;444;445;446;447;448;449;450;452;453;455;456;470;473;475;484;485;486;489;490;491;492;493;494;496,0,1,1,0,
7DK4,"S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,0,A,a,b,403;405;417;421;446;447;449;452;455;456;473;475;482;483;484;485;486;487;488;489;490;491;493;494;496;498;501;504;505,0,1,1,0,
7DK4,"S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,1,B,c,d,403;405;417;446;447;449;452;453;455;456;472;473;474;475;476;482;483;484;485;486;487;488;489;490;491;493;494;496;501;502;504;505,0,1,1,0,
7DK4,"S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,2,C,e,f,403;405;417;421;446;447;449;455;456;475;476;483;484;485;486;487;489;490;491;493;494;496;501;504;505,0,1,1,0,
7DK5,"S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab",12/2/2020,Antibody,2H2,,,,0,A,a,b,403;405;406;417;421;446;447;449;452;453;455;456;472;473;474;475;476;480;482;483;484;485;486;487;488;489;490;491;492;493;494;496;498;501;504;505,0,1,1,0,
7DK6,"S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,0,A,a,b,403;405;417;446;447;449;453;455;456;472;473;474;475;480;482;483;484;485;486;487;488;489;490;491;493;494;496;498;501;504;505,0,1,1,0,
7DK6,"S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,1,B,c,d,403;405;406;417;420;421;447;449;452;453;455;456;472;473;474;475;476;480;482;483;484;485;486;487;488;489;490;493;494;496;498;501;502;504;505,0,1,1,0,
7DK7,"S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,0,A,a,b,403;405;417;421;446;447;449;452;453;455;456;472;473;475;476;480;483;484;485;486;487;488;489;490;491;492;493;494;496;498;501;504;505,0,1,1,0,
7DK7,"S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,1,B,c,d,403;405;406;417;446;447;449;452;453;455;456;473;475;476;480;483;484;485;486;487;488;489;490;491;492;493;494;496;498;501;505,0,1,1,0,
7DK7,"S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.",12/2/2020,Antibody,2H2,,,,2,C,e,f,446;447;449;475;483;484;485;486;487;489;493;494;496;498;500;501,0,1,1,0,
7DPM,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2/17/2021,Antibody,MW06,,,,0,C,A,B,369;372;374;375;376;377;378;379;383;384;385;404;407;408;435;436;437;439;440;502;503;506;508,0,1,1,0,
7DPM,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2/17/2021,Antibody,MW06,,,,1,F,D,E,369;372;374;375;376;377;378;379;383;384;385;404;407;408;435;436;437;439;440;502;503;506;508,0,1,1,0,
7DPM,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2/17/2021,Antibody,MW06,,,,2,I,G,H,369;372;374;375;376;377;378;379;380;383;384;385;404;407;408;435;436;437;439;440;502;503;506;508,0,1,1,0,
7DPM,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2/17/2021,Antibody,MW06,,,,3,L,J,K,369;372;374;375;376;377;378;379;380;383;384;385;404;407;408;435;436;437;439;440;502;503;506;508,0,1,1,0,
7DX4,The structure of FC08 Fab-hA.CE2-RBD complex,4/21/2021,Antibody,FC08,,,,0,E,H,L,337;340;344;346;348;351;352;354;355;356;357;359;360;394;396;399;449;450;452;457;462;464;465;466;467;468;469;470;471;472;480;482;484;490;492;494,0,1,1,0,
7DZX,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2,6/2/2021,Antibody,8D2,,,,0,C,H,L,68;71;73;75;76;77;97;181;183;185;211;212;213;214;218;259;262;684,1,0,0,0,
7DZY,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490,6/2/2021,Antibody,2490,,,,0,A,O,P,27;30;64;66;68;70;71;72;73;76;97;98;181;182;183;184;185;186;211;212;213;214;215;218;245;247;249;250;258;260;261;264,1,0,0,0,
7DZY,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490,6/2/2021,Antibody,2490,,,,1,B,H,L,30;64;66;68;69;70;71;72;73;76;95;97;98;145;152;180;181;182;183;184;185;186;187;210;212;213;214;215;218;246;261;262;264,1,0,0,0,
7DZY,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490,6/2/2021,Antibody,2490,,,,2,C,M,N,66;68;70;72;73;76;77;78;180;183;184;185;211;212;213;214;215;218;245;247;259;261;262;264;684,1,0,0,0,
7.00E+23,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),5/5/2021,Antibody,CA521,,,,0,A,B,C,417;447;449;452;455;456;475;484;485;486;489;490;492;493;494;496,0,1,1,0,
7.00E+39,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),9/1/2021,Antibody,Ab4,,,,0,A,C,B,456;472;474;475;476;477;478;479;480;483;485;486;487;488;489,0,1,1,0,
7E3B,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),9/1/2021,Antibody,Ab5,,,,0,A,B,C,344;345;346;348;349;351;352;354;401;438;441;442;444;445;446;448;449;450;451;452;466;468;494;497;507;509,0,1,1,0,
7E3C,SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD),9/1/2021,Antibody,Ab1,,,,0,A,B,C,403;405;406;408;409;415;416;417;419;420;421;447;449;453;455;456;457;458;459;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7E3K,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,13G9,,,,0,A,D,E,455;456;458;473;475;476;477;478;483;484;485;486;487;488;489;493,0,1,1,0,
7E3K,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,13G9,,,,1,B,F,G,455;456;458;473;475;476;477;478;483;484;485;486;487;488;489;493,0,1,1,0,
7E3K,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,13G9,,,,2,C,H,L,455;456;458;473;475;476;477;478;483;484;485;486;487;488;489;493,0,1,1,0,
7E3L,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,58G6,,,,0,A,D,E,455;456;458;473;475;476;477;478;479;483;485;486;487;488;489;493,0,1,1,0,
7E3L,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,58G6,,,,1,B,F,G,455;456;458;473;475;476;477;478;479;483;485;486;487;488;489;493,0,1,1,0,
7E3L,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,Antibody,58G6,,,,2,C,H,L,455;456;458;473;475;476;477;478;479;483;485;486;487;488;489;493,0,1,1,0,
7E3O,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617,9/15/2021,Antibody,nCoV617,,,,0,R,H,L,346;349;351;352;444;446;447;448;449;450;452;455;456;468;470;471;472;483;484;485;486;489;490;492;493;494;496,0,1,1,0,
7E5O,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,9/8/2021,Antibody,NT-193,,,,0,A,H,L,403;404;405;406;408;409;415;416;417;418;420;421;447;449;453;455;456;475;487;489;490;493;494;496;498;501;502;503;504;505,0,1,1,0,518;519;520;521
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,0,A,L,H,372;375;376;377;378;380;404;405;407;408;411;412;413;414;427;429;435;437;502;503;504;508,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,1,A,P,Q,144;145;147;148;150;152;153;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,2,A,M,U,447;449;470;471;472;481;482;483;484;485;486;489;490;492;493;494,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,3,B,W,R,144;145;147;148;150;152;153;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,4,B,N,D,372;374;375;376;377;378;380;404;405;407;408;411;412;413;414;427;429;433;435;437;502;503;504;508,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,5,B,T,V,447;449;470;471;472;481;482;483;484;485;486;489;490;492;493;494,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,6,C,O,E,369;372;375;376;377;378;380;404;405;407;408;411;412;413;414;427;429;435;437;503;504;508,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,7,C,I,K,447;449;452;455;470;471;472;481;482;483;484;485;486;489;490;492;493;494,0,1,1,0,
7E5R,SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,Antibody,H014,P17,FC05,,8,C,X,S,144;145;147;148;150;152;153;155;246;248;249;251;256;257,1,0,0,0,252;253;254;255
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,0,A,R,O,375;403;437;439;440;443;444;445;447;449;494;496;498;499;500;501;502;503;504;505;506,0,1,1,0,
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,1,A,P,N,142;144;145;146;147;148;150;152;155;246;248;249;251;256,1,0,0,0,252;253;254;255
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,2,B,U,Q,142;144;145;147;152;155;158;246;248;249;251;256,1,0,0,0,252;253;254;255
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,3,B,I,K,351;447;449;450;452;455;456;469;470;471;472;473;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,4,B,L,D,369;372;373;374;375;376;377;378;380;384;404;405;407;408;411;412;413;427;435;437;439;502;503;504;506;508,0,1,1,0,
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,5,C,V,S,142;144;145;147;152;155;158;245;246;248;249;251;256,1,0,0,0,252;253;254;255
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,6,C,E,H,369;372;373;374;375;376;377;378;380;381;384;404;405;407;408;411;412;413;414;427;435;437;439;502;503;504;508,0,1,1,0,
7E5S,SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,Antibody,H014,P17,FC05,HB27,7,C,J,T,351;447;449;452;455;456;470;471;472;473;479;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,
7E5Y,Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD,6/23/2021,Antibody,2B11,,,,0,A,C,B,403;405;408;415;417;420;421;455;456;457;458;460;473;474;475;476;477;478;486;487;489;493;501;502;504;505,0,1,1,0,517;518;519;520;521
7E5Y,Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD,6/23/2021,Antibody,2B11,,,,1,R,H,L,403;405;408;415;417;419;420;421;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;501;502;504;505,0,1,1,0,517;518;519;520;521
7E7X,SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab,6/9/2021,Antibody,N11,,,,0,A,H,L,144;145;146;147;148;150;152;246;247;248;249;250;251;252;253;254;255;257,1,0,0,0,19;20;21;22;23;24;25;26;68;69;70;71;72;73;74;75;76;77;78;79;80;176;177;178;179;180;181;182;183;184;185;186;187;188;207;208;209;210;211;212;213;214;215;216;217;218;219;220
7E7X,SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab,6/9/2021,Antibody,N11,,,,1,B,M,N,144;145;146;147;148;150;152;153;246;247;248;249;250;251;252;253;255;257,1,0,0,0,19;20;21;22;23;24;25;26;27;28;29;30;31;32;33;34;35;36;53;54;55;56;57;58;59;60;61;67;68;69;70;71;72;73;74;75;76;77;78;79;80;97;98;176;177;178;179;180;181;182;183;184;185;186;187;188;207;208;209;210;211;212;213;214;215;216;217;218;219;220;221;222
7E7Y,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab,6/9/2021,Antibody,BD-623,,,,0,E,C,D,477;478;479;481;483;484;485;486;488;489;490,0,1,1,0,
7E7Y,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab,6/9/2021,Antibody,BD-623,,,,1,R,A,B,456;473;475;476;477;478;479;481;483;484;485;486;487;488;489;490,0,1,1,0,517;518;519;520;521
7.00E+86,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab,6/9/2021,Antibody,BD-508,,,,0,C,A,B,403;405;415;416;417;419;420;421;455;456;457;458;459;460;473;475;476;477;484;486;487;489;490;493;494;496;497;498;500;501;502;504;505,0,1,1,0,444;445;446;447;448;449
7.00E+88,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,6/9/2021,Antibody,BD-515,,,,0,C,A,B,403;405;415;416;417;420;421;455;456;457;458;459;460;473;475;476;477;478;486;487;489;493;496;498;501;502;504;505,0,1,1,0,517;518;519;520;521
7.00E+88,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,6/9/2021,Antibody,BD-515,,,,1,F,D,E,403;405;406;415;416;417;420;421;455;456;457;458;459;460;473;474;475;476;477;478;486;487;489;493;496;498;501;502;504;505,0,1,1,0,517;518;519;520;521
7.00E+88,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,6/9/2021,Antibody,BD-515,,,,2,I,G,H,403;405;415;416;417;420;421;455;456;457;458;459;460;473;474;475;476;477;478;486;487;489;493;496;498;501;502;504;505,0,1,1,0,517;518;519;520;521
7.00E+88,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,6/9/2021,Antibody,BD-515,,,,3,L,J,K,403;405;408;415;416;417;420;421;455;456;457;458;459;460;473;474;475;476;477;478;486;487;489;493;496;501;502;504;505,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,0,A,M,J,349;351;446;447;449;450;452;470;472;480;481;482;483;484;485;490;492;493;494,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,1,A,H,L,14;15;16;142;144;146;147;148;154;156;157;158;161;246;248;249;250;251;252;253;254;256;257,1,0,0,0,69;70;71;72;73;74;75;76;77;177;178;179;180;181;182;183;184;185;186
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,2,A,O,Q,403;405;415;416;417;420;421;447;449;453;455;456;458;460;473;475;476;477;478;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,3,B,K,I,349;351;447;449;450;452;470;472;480;481;482;483;484;485;490;492;493;494,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,4,B,N,P,403;405;415;416;417;419;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,5,B,T,V,14;15;16;17;142;144;146;147;148;152;154;156;157;158;161;246;248;249;250;251;252;253;254;256;257,1,0,0,0,69;70;71;72;73;74;75;76;77;177;178;179;180;181;182;183;184;185;186
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,6,C,D,E,403;405;415;416;417;419;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;505,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,7,C,a,Z,349;446;447;449;450;452;470;471;472;479;480;481;482;483;484;485;490;492;493;494,0,1,1,0,517;518;519;520;521
7E8C,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,Antibody,604,N9,368-2,,8,C,S,U,14;15;16;136;142;144;146;147;148;152;154;156;157;158;161;246;248;249;250;251;252;253;254;256;257,1,0,0,0,69;70;71;72;73;74;75;76;77;177;178;179;180;181;182;183;184;185;186
7E8F,SARS-CoV-2 NTD in complex with N9 Fab,6/9/2021,Antibody,N9,,,,0,A,H,L,14;15;16;17;142;144;146;147;148;152;154;156;157;158;161;246;248;249;250;251;252;253;254;256;257,1,0,0,0,69;70;71;72;73;74;75;76;77;177;178;179;180;181;182;183;184;185;186
7E8F,SARS-CoV-2 NTD in complex with N9 Fab,6/9/2021,Antibody,N9,,,,1,R,C,B,349;447;449;450;452;470;472;479;480;481;482;483;484;485;488;490;492;493;494;496,0,1,1,0,517;518;519;520;521
7E8F,SARS-CoV-2 NTD in complex with N9 Fab,6/9/2021,Antibody,N9,,,,2,R,D,E,403;405;408;415;416;417;419;420;421;447;449;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;503;504;505,0,1,1,0,517;518;519;520;521
7E8M,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD,5/26/2021,Antibody,P2C-1F11,,,,0,E,H,L,403;405;415;416;417;420;421;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,517;518;519
7EAM,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6,3/17/2021,Antibody,7D6,,,,0,A,H,L,346;348;349;351;352;353;354;355;357;359;393;394;396;398;462;465;466;468;469;470;471;516;518;519;520;521,0,1,1,0,
7EAM,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6,3/17/2021,Antibody,7D6,,,,1,B,C,D,346;348;349;351;352;353;354;355;357;359;393;394;396;398;462;465;466;468;469;470;471;516;518;519;520;521,0,1,1,0,
7EAN,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6,3/31/2021,Antibody,6D6,,,,0,A,H,L,348;349;351;352;353;354;355;356;357;393;394;396;426;457;459;461;462;463;464;465;466;467;468;469;470;471;516;518;520;521,0,1,1,0,
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,0,A,H,L,458;473;474;475;476;477;478;479;485;486;487;489,0,1,1,0,445;446
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,1,A,D,O,369;372;374;375;376;377;378;384;404;405;407;408;502;503;504;505;508,0,1,1,0,445;446
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,2,B,E,P,369;372;374;375;376;377;378;384;404;405;407;408;502;503;504;505;508,0,1,1,0,445;446
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,3,B,I,M,458;473;474;475;476;477;478;479;485;486;487;489,0,1,1,0,445;446
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,4,C,F,Q,369;372;374;375;376;377;378;384;404;405;407;408;502;503;504;505;508,0,1,1,0,445;446
7EH5,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,Antibody,RBD-chAb15,RBD-chAb45,,,5,C,J,N,458;473;474;475;476;477;478;479;485;486;487;489,0,1,1,0,445;446
7EJ4,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,6/23/2021,Antibody,RBD-chAb-25,,,,0,A,H,L,403;405;417;439;444;447;449;453;455;490;493;494;495;496;497;498;500;501;502;503;504;505;506,0,1,1,0,445;446
7EJ4,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,6/23/2021,Antibody,RBD-chAb-25,,,,1,B,I,M,403;405;417;439;444;447;449;453;455;484;490;493;494;495;496;497;498;500;501;502;503;504;505;506,0,1,1,0,445;446
7EJ4,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,6/23/2021,Antibody,RBD-chAb-25,,,,2,C,J,N,403;405;417;439;444;447;449;453;455;490;493;494;495;496;497;498;500;501;502;503;504;505;506,0,1,1,0,445;446
7EJ5,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45,6/23/2021,Antibody,RBD-chAb-45,,,,0,A,H,L,456;458;474;475;476;477;478;479;481;485;486;487;488;489,0,1,1,0,445;446
7EJ5,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45,6/23/2021,Antibody,RBD-chAb-45,,,,1,B,I,M,458;473;474;475;476;477;478;479;480;485;486;487;488;489,0,1,1,0,445;446
7EJ5,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45,6/23/2021,Antibody,RBD-chAb-45,,,,2,C,J,N,456;474;475;476;477;478;479;480;485;486;487;488;489,0,1,1,0,445;446
7EY5,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,9/8/2021,Antibody,"BD-771
BD-821",,,,0,A,B,C,346;439;440;441;443;444;445;446;498;499;500,0,1,1,0,
7EY5,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,9/8/2021,Antibody,"BD-771
BD-821",,,,1,A,H,L,415;416;417;420;421;447;449;455;456;460;473;475;476;478;479;480;483;485;486;487;488;489;490;493;494;496,0,1,1,0,
7EYA,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab,9/8/2021,Antibody,BD-804,,,,0,R,H,L,345;346;348;349;351;352;440;441;444;445;446;447;448;449;450;451;452;470;484;490;492;494;499,0,1,1,0,
7EZV,local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab,9/8/2021,Antibody,BD-812,,,,0,A,M,N,417;420;421;453;455;456;458;473;475;476;477;478;480;481;483;484;485;486;487;488;489;490;493,0,1,1,0,
7EZV,local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab,9/8/2021,Antibody,BD-812,,,,1,A,H,L,345;346;439;440;441;442;443;444;445;446;448;450;498;499;500;502,0,1,1,0,
7F62,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),8/4/2021,Antibody,chAb-25,,,,0,A,H,L,403;405;417;439;444;449;453;455;490;493;494;495;496;497;498;500;501;502;503;504;505;506,0,1,1,0,445;446
7F63,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refinement of S-RBD and chAb-45 region),8/4/2021,Antibody,chAb-45,,,,0,A,H,L,456;458;474;475;476;477;478;479;481;485;486;487;488;489,0,1,1,0,445;446
7JMO,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04,8/26/2020,Antibody,COVA2-04,,,,0,A,H,L,403;405;415;416;417;420;421;447;449;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;494;495;496;498;500;501;502;504;505,0,1,1,0,
7JMP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39,8/26/2020,Antibody,COVA2-39,,,,0,A,H,L,417;447;449;455;456;473;475;476;477;478;483;484;485;486;487;488;489;490;493;494;496,0,1,1,0,360;361;362;363;364;365;370;385;386;387;388;389;390;391
7JMW,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab,10/14/2020,Antibody,COVA1-16,,,,0,A,H,L,369;374;377;378;379;380;381;383;384;385;405;408;411;412;413;414;415;416;419;427;428;429,0,1,0,0,
7JV2,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains),10/14/2020,Antibody,S2H13,,,,0,A,H,L,470;472;478;479;481;482;483;484;485;486;488;489;490;493;494,0,1,1,0,462;463;464;465;466;467
7JV4,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open),10/14/2020,Antibody,S2H13,,,,0,A,H,L,470;472;480;481;482;483;484;485;486;488;489;490;493;494,0,1,1,0,445;446;475;476;477;478;502;518;519
7JV4,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open),10/14/2020,Antibody,S2H13,,,,1,B,D,E,481;482;483;484;485;486;488;489;490;493,0,1,1,0,443;444;445;446;458;459;460;461;467;468;469;470;471;472;473;474;475;476;477;478;479;516;517;518;519;520;521
7JV4,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open),10/14/2020,Antibody,S2H13,,,,2,C,F,G,480;481;482;483;484;485;486;488;489;490;493,0,1,1,0,443;444;445;446;447;455;456;457;458;459;460;461;467;468;469;470;471;472;473;474;475;476;477;478;479
7JV6,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation),10/14/2020,Antibody,S2H13,,,,0,A,H,L,480;481;482;483;484;485;486;488;489;490;493;494,0,1,1,0,445;446;468;469;470;471;472;473;474;475;476;477;478;479;502
7JV6,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation),10/14/2020,Antibody,S2H13,,,,1,B,C,D,480;481;482;483;484;485;486;488;489;490;493;494,0,1,1,0,445;446;468;469;470;471;472;473;474;475;476;477;478;479;502
7JV6,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation),10/14/2020,Antibody,S2H13,,,,2,E,F,G,480;481;482;483;484;485;486;488;489;490;493;494,0,1,1,0,445;446;468;469;470;471;472;473;474;475;476;477;478;479;502
7JVA,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains),10/14/2020,Antibody,S2A4,,,,0,A,H,L,369;370;371;372;374;375;376;377;378;379;380;383;384;385;388;407;408;411;433;435;437;503,0,1,1,0,484;485
7JVC,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment,10/14/2020,Antibody,S2A4,,,,0,A,H,L,369;370;371;372;374;375;376;377;378;379;380;383;384;385;386;407;408;411;433;435;437;503,0,1,1,0,445;446;502
7JVC,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment,10/14/2020,Antibody,S2A4,,,,1,B,C,D,369;370;371;372;374;375;376;377;378;379;380;383;384;385;386;407;408;411;433;435;437;503,0,1,1,0,445;446;502
7JVC,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment,10/14/2020,Antibody,S2A4,,,,2,E,F,G,369;370;371;372;374;375;376;377;378;379;380;383;384;385;386;407;408;411;433;435;437;503,0,1,1,0,445;446;502
7JW0,SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment,10/14/2020,Antibody,S304,,,,0,A,H,L,365;369;370;377;378;379;380;382;383;384;385;386;388;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,445;446
7JW0,SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment,10/14/2020,Antibody,S304,,,,1,B,D,C,365;369;370;377;378;379;380;382;383;384;385;386;388;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,445;446
7JW0,SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment,10/14/2020,Antibody,S304,,,,2,E,G,F,365;369;370;377;378;379;380;382;383;384;385;386;388;390;392;411;412;413;414;427;428;429;430;517,0,1,0,0,445;446
7JX3,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,Antibody,S309,S2H14,S304,,0,R,C,D,403;405;417;445;446;447;449;455;456;473;475;484;489;493;494;495;496;497;498;499;500;501;502;504;505,0,1,1,0,
7JX3,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,Antibody,S309,S2H14,S304,,1,R,A,B,334;335;337;339;340;341;343;344;345;346;354;356;358;361;440;441;444;509,0,1,1,0,
7JX3,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,Antibody,S309,S2H14,S304,,2,R,H,L,366;369;370;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;515;517;527,0,1,0,0,
7K43,SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2M11,,,,0,A,H,L,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7K43,SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2M11,,,,1,B,C,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7K43,SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2M11,,,,2,E,F,G,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7K45,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains),10/7/2020,Antibody,S2E12,,,,0,B,H,L,417;455;456;473;475;476;477;478;480;483;484;485;486;487;488;489;490;493,0,1,1,0,
7K4N,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2E12,,,,0,A,H,L,417;453;455;456;473;475;476;477;478;480;481;483;484;485;486;487;488;489;490;493,0,1,1,0,
7K4N,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2E12,,,,1,B,C,D,417;453;455;456;473;475;476;477;478;480;481;483;484;485;486;487;488;489;490;493,0,1,1,0,
7K4N,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment,10/7/2020,Antibody,S2E12,,,,2,E,F,G,417;453;455;456;473;475;476;477;478;480;481;483;484;485;486;487;488;489;490;493,0,1,1,0,
7K8M,"Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102",10/21/2020,Antibody,C102,,,,0,E,A,B,403;405;415;416;417;420;421;447;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7K8S,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",10/21/2020,Antibody,C002,,,,0,A,H,L,417;446;447;449;450;452;453;455;456;470;471;472;479;481;482;483;484;485;486;489;490;492;493;494;496,0,1,1,0,
7K8S,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",10/21/2020,Antibody,C002,,,,1,B,O,P,446;447;449;450;452;453;455;456;470;482;483;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7K8S,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",10/21/2020,Antibody,C002,,,,2,C,M,N,417;446;447;449;450;452;453;455;456;470;471;472;481;482;483;484;485;486;489;490;491;492;493;494;496,0,1,1,0,
7K8T,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)",10/21/2020,Antibody,C002,,,,0,A,O,P,444;449;450;452;453;455;456;470;472;473;475;479;481;482;483;484;485;486;487;489;490;492;493;494;496;505,0,1,1,0,445;446;502
7K8T,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)",10/21/2020,Antibody,C002,,,,1,B,M,N,444;449;452;453;455;456;470;472;473;481;482;483;484;485;486;489;490;492;493;494,0,1,1,0,445;446;502
7K8T,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)",10/21/2020,Antibody,C002,,,,2,C,H,L,349;417;449;450;452;455;456;470;472;473;475;479;481;482;483;485;486;487;489;490;491;492;493;494;496,0,1,1,0,445;446;502
7K8U,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104",10/21/2020,Antibody,C104,,,,0,"A,B",H,L,378;408;414;444;446;449;450;452;470;472;483;484;485;486;490;492;494;502;503,0,1,1,1,
7K8V,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110",10/21/2020,Antibody,C110,,,,0,"A,B",H,L,345;346;347;349;351;352;408;438;441;442;448;449;450;452;470;471;490;492;494;498;499;500,0,1,1,1,443;444;445;446;447;477;478;479;480;481;482;483;502
7K8V,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110",10/21/2020,Antibody,C110,,,,1,C,M,N,345;346;347;349;351;352;441;442;448;449;450;451;452;470;471;490;492;493;494;498;499;500,0,1,1,0,443;444;445;446;447;477;478;479;480;481;482;483;502
7K8W,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119",10/21/2020,Antibody,C119,,,,0,"A,B",H,L,403;404;405;408;413;415;444;445;446;447;448;449;450;452;484;490;493;494;496;498;499;500;501;502;503;504;505,0,1,1,1,519
7K8W,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119",10/21/2020,Antibody,C119,,,,1,G,N,S,403;405;444;445;446;447;448;449;450;452;453;470;484;490;492;493;494;496;498;499;500;501;505,0,1,1,0,
7K8X,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)",10/21/2020,Antibody,C121,,,,0,A,E,G,447;449;452;455;456;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7K8X,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)",10/21/2020,Antibody,C121,,,,1,"B,C",D,F,376;378;408;411;413;414;415;416;419;447;449;452;455;456;470;472;475;476;483;484;485;486;487;489;490;492;493;494;496;498,0,1,1,1,
7K8Y,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)",10/21/2020,Antibody,C121,,,,0,"B,D",G,I,378;408;411;413;414;415;419;446;447;449;452;455;456;470;475;484;485;486;487;489;490;492;493;494;496;498,0,1,1,1,
7K8Z,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135",10/21/2020,Antibody,C135,,,,0,A,H,L,345;346;373;437;438;439;440;441;448;450;499;500,0,1,1,0,443;444;445;446;447;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;502
7K8Z,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135",10/21/2020,Antibody,C135,,,,1,C,M,N,345;346;373;436;437;438;439;440;441;443;444;448;450;499;500,0,1,1,0,445;446;447;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485
7K90,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144",10/21/2020,Antibody,C144,,,,0,A,M,N,417;447;449;455;456;470;472;475;476;484;486;487;489;490;491;493;494;496;498;500,0,1,1,0,502
7K90,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144",10/21/2020,Antibody,C144,,,,1,B,H,L,417;447;449;455;456;470;472;475;484;486;487;489;490;491;492;493;494;496;498;500,0,1,1,0,502
7K90,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144",10/21/2020,Antibody,C144,,,,2,C,O,P,417;447;449;455;456;470;472;473;475;476;484;486;487;489;490;491;492;493;494;496;498;500,0,1,1,0,502
7K9H,"SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation)",9/29/2021,Antibody,2B04,,,,0,"A,B",H,L,404;408;411;414;446;447;449;452;470;472;483;484;485;486;487;489;490;491;492;493;494;496;503,0,1,1,1,
7K9H,"SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation)",9/29/2021,Antibody,2B04,,,,1,C,I,M,447;449;452;470;472;484;485;486;487;489;490;492;493;494;495;496;498,0,1,1,0,
7K9I,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement),9/29/2021,Antibody,2B04,,,,0,A,H,L,447;449;452;455;456;470;472;484;485;486;487;489;490;491;492;493;494;496;498,0,1,1,0,
7K9J,SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation),9/29/2021,Antibody,2H04,,,,0,A,H,L,337;339;340;343;344;345;346;440;441;442;443;444;445;446;448;450;451;499,0,1,1,0,469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488
7K9J,SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation),9/29/2021,Antibody,2H04,,,,1,B,I,M,337;339;340;343;344;345;346;440;441;442;443;444;445;446;448;450;499,0,1,1,0,469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488
7K9J,SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation),9/29/2021,Antibody,2H04,,,,2,C,J,N,337;339;340;343;344;345;346;356;440;441;442;443;444;445;446;448;450;499,0,1,1,0,469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488
7K9K,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement),9/29/2021,Antibody,2H04,,,,0,A,H,L,337;339;340;343;344;345;346;356;440;441;442;444;445;446;448;450;499,0,1,1,0,469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488
7K9Z,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,10/28/2020,Antibody,298,52,,,0,E,H,L,348;349;351;352;354;355;357;450;452;462;464;465;466;467;468;469;470;471;472;481;482;483;484;490;491;492;493;494,0,1,1,0,
7K9Z,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,10/28/2020,Antibody,298,52,,,1,E,B,A,455;456;474;475;476;477;478;484;485;486;487;489;490;493,0,1,1,0,
7KFV,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab),12/2/2020,Antibody,C1A-B12,,,,0,A,H,L,403;405;406;415;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;494;495;496;498;500;501;502;503;504;505,0,1,1,0,
7KFV,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab),12/2/2020,Antibody,C1A-B12,,,,1,B,C,D,403;405;406;415;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;494;495;496;498;500;501;502;503;504;505,0,1,1,0,
7KFV,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab),12/2/2020,Antibody,C1A-B12,,,,2,E,F,G,403;405;406;415;416;417;419;420;421;447;453;455;456;458;460;473;475;476;477;486;487;489;490;493;495;496;498;500;501;502;504;505,0,1,1,0,
7KFW,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab),12/2/2020,Antibody,C1A-B3,,,,0,A,H,L,403;405;406;415;416;417;419;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7KFW,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab),12/2/2020,Antibody,C1A-B3,,,,1,B,C,D,403;405;406;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7KFW,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab),12/2/2020,Antibody,C1A-B3,,,,2,E,F,G,403;405;406;415;416;417;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7KFX,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab),12/2/2020,Antibody,C1A-C2,,,,0,A,H,L,403;405;406;415;417;420;421;447;449;453;455;456;458;459;460;473;474;475;476;477;486;487;489;490;493;495;496;498;500;501;502;504;505,0,1,1,0,
7KFY,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab),12/2/2020,Antibody,C1A-F10,,,,0,A,H,L,403;405;406;415;416;417;419;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;500;501;502;504;505,0,1,1,0,
7KLG,SARS-CoV-2 RBD in complex with Fab 15033,2/10/2021,Antibody,15033,,,,0,A,H,L,403;405;406;409;415;416;417;420;421;453;455;456;458;473;475;476;477;484;485;486;487;489;490;493;494;496;502;504;505,0,1,1,0,
7KLG,SARS-CoV-2 RBD in complex with Fab 15033,2/10/2021,Antibody,15033,,,,1,B,I,M,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;477;484;485;486;487;489;490;493;496;502;504;505,0,1,1,0,
7KLH,SARS-CoV-2 RBD in complex with Fab 15033-7,2/10/2021,Antibody,15033-7,,,,0,A,H,L,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;484;485;486;487;489;490;493;494;496;502;504;505,0,1,1,0,
7KLH,SARS-CoV-2 RBD in complex with Fab 15033-7,2/10/2021,Antibody,15033-7,,,,1,B,I,M,403;405;406;408;409;416;417;420;421;453;455;456;473;475;476;484;485;486;487;489;490;493;496;502;504;505,0,1,1,0,
7KMG,LY-CoV555 neutralizing antibody against SARS-CoV-2,1/27/2021,Antibody,LY-CoV555,,,,0,C,A,B,351;446;447;449;450;452;455;456;470;478;481;483;484;485;486;488;489;490;492;493;494;496,0,1,1,0,
7KMG,LY-CoV555 neutralizing antibody against SARS-CoV-2,1/27/2021,Antibody,LY-CoV555,,,,1,F,D,E,351;446;447;449;450;452;453;455;456;470;478;481;483;484;485;486;488;489;490;492;493;494;496,0,1,1,0,
7KMH,LY-CoV488 neutralizing antibody against SARS-CoV-2,1/27/2021,Antibody,LY-CoV488,,,,0,C,A,B,403;405;415;416;417;419;420;421;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,
7KMI,LY-CoV481 neutralizing antibody against SARS-CoV-2,1/27/2021,Antibody,LY-CoV481,,,,0,C,A,B,403;405;408;409;415;416;417;420;421;447;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;500;501;502;503;504;505,0,1,1,0,
7KMK,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound",2/10/2021,Antibody,15033-7,,,,0,A,H,L,403;405;406;408;409;416;417;420;421;453;455;456;473;475;476;484;485;486;487;489;490;493;502;504;505,0,1,1,0,
7KMK,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound",2/10/2021,Antibody,15033-7,,,,1,B,I,M,403;405;406;408;409;416;417;420;421;453;455;456;473;475;476;484;485;486;487;489;490;493;494;502;504;505,0,1,1,0,
7KML,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound",2/10/2021,Antibody,15033-7,,,,0,A,H,L,403;405;406;409;417;421;455;456;457;473;475;476;484;485;486;487;489;493;495;501;502;504;505,0,1,1,0,
7KML,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound",2/10/2021,Antibody,15033-7,,,,1,B,I,M,403;405;406;409;417;421;455;456;457;473;475;476;484;485;486;487;489;493;495;501;502;504;505,0,1,1,0,
7KML,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound",2/10/2021,Antibody,15033-7,,,,2,C,J,N,403;405;406;409;417;421;455;456;457;473;475;476;484;485;486;487;489;493;495;501;502;504;505,0,1,1,0,
7KN3,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-B8 Fab,9/22/2021,Antibody,S-B8,,,,0,A,H,L,447;449;452;453;455;456;473;474;475;476;477;478;483;484;485;486;487;489;490;492;493;494;496;498;501;505,0,1,1,0,
7KN3,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-B8 Fab,9/22/2021,Antibody,S-B8,,,,1,B,M,N,447;449;452;453;455;456;473;474;475;476;477;478;483;484;485;486;487;489;490;492;493;494;496;498;501;505,0,1,1,0,
7KN4,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-E6 Fab,9/22/2021,Antibody,S-E6,,,,0,A,H,L,403;405;449;455;456;473;475;476;484;486;487;489;490;493;494;496;502;504;505,0,1,1,0,519
7KN4,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-E6 Fab,9/22/2021,Antibody,S-E6,,,,1,B,M,N,403;405;417;449;455;456;473;475;476;483;484;486;487;489;490;493;494;496;502;504;505,0,1,1,0,367;372;373;383;439;444;445;446;447;448;520
7KN6,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody Fab CC12.3,1/20/2021,"Antibody
Nanobody",CC12.3,VHH V,,,0,A,H,L,403;405;415;416;417;420;421;447;455;456;457;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,517;518;519;520;521
7KN7,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody Fab CC12.3,1/20/2021,"Antibody
Nanobody",CC12.3,VHH W,,,0,A,H,L,403;405;415;416;417;420;421;455;456;457;458;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,516;517;518;519;520
7KQE,SARS-CoV-2 spike glycoprotein:Fab 3D11 complex,5/26/2021,Antibody,3D11,,,,0,A,H,L,366;369;370;372;374;375;376;377;378;379;383;384;385;407;408;411;435;503,0,1,1,0,
7KQE,SARS-CoV-2 spike glycoprotein:Fab 3D11 complex,5/26/2021,Antibody,3D11,,,,1,B,I,N,366;369;370;372;374;375;376;377;378;379;383;384;385;407;408;411;435;503,0,1,1,0,
7KQE,SARS-CoV-2 spike glycoprotein:Fab 3D11 complex,5/26/2021,Antibody,3D11,,,,2,C,J,M,366;369;370;372;374;375;376;377;378;379;383;384;385;407;408;411;435;503,0,1,1,0,
7KS9,Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab,2/10/2021,Antibody,910-30,,,,0,B,H,L,403;405;406;415;417;419;420;421;447;453;455;456;458;460;473;475;476;477;478;486;487;489;493;494;495;496;498;500;501;502;503;504;505,0,1,1,0,
7KXJ,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric",2/3/2021,Antibody,15033-7,,,,0,A,H,L,403;405;409;416;417;420;421;453;455;456;473;475;476;484;485;486;487;489;493;502;504;505,0,1,1,0,
7KXJ,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric",2/3/2021,Antibody,15033-7,,,,1,B,I,M,403;405;406;408;409;416;417;420;421;453;455;456;457;473;475;476;484;485;486;487;489;493;494;496;502;504;505,0,1,1,0,
7KXJ,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric",2/3/2021,Antibody,15033-7,,,,2,C,J,N,403;417;420;421;447;453;455;456;460;473;475;476;484;485;486;487;489;490;493;494;496;501;504;505,0,1,1,0,
7KXK,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation",2/3/2021,Antibody,15033-7,,,,0,A,H,L,403;405;406;409;417;420;421;449;453;455;456;473;475;476;484;485;486;487;488;489;493;494;496;502;504;505,0,1,1,0,
7KXK,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation",2/3/2021,Antibody,15033-7,,,,1,B,I,M,403;405;406;417;447;455;456;473;475;484;485;486;487;489;490;493;496;498;501;504;505,0,1,1,0,
7KXK,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation",2/3/2021,Antibody,15033-7,,,,2,C,J,N,403;405;417;455;456;475;484;485;486;487;489;490;493;496;502;504;505,0,1,1,0,
7KZB,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2/3/2021,Antibody,CR3014-C8,CR3022-B6,,,0,C,A,B,417;421;455;456;473;474;475;476;477;478;484;485;486;487;489;493;496,0,1,1,0,
7KZB,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2/3/2021,Antibody,CR3014-C8,CR3022-B6,,,1,C,H,L,369;370;371;372;374;376;377;378;379;380;383;384;385;386;408;411;412;413;427;428;430,0,1,0,0,
7L02,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12,12/30/2020,Antibody,2G12,,,,0,A,M,K,925;932;936;937;940;941,0,0,0,0,445;446;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;502
7L06,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12,12/30/2020,Antibody,2G12,,,,0,A,M,K,936;937;939;940;941,0,0,0,0,445;446;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;502
7L06,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12,12/30/2020,Antibody,2G12,,,,1,B,G,E,936;937;939;940;941,0,0,0,0,445;446;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;502
7L09,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D refinement,12/30/2020,Antibody,2G12,,,,0,A,M,K,925;932;936;937;940;941,0,0,0,0,445;446;455;456;457;458;459;460;461;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;502
7L0N,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,Antibody,S309,S304,,,0,R,A,B,329;331;333;334;335;336;337;339;340;341;343;344;345;346;354;356;358;361;362;364;440;441;509,0,1,1,0,
7L0N,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,Antibody,S309,S304,,,1,R,H,L,369;370;378;379;380;381;382;383;384;385;386;387;388;389;390;411;412;413;427;428;429;430;517;527;530,0,1,0,0,
7L0N,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,Antibody,S309,S304,,,2,S,M,N,366;369;370;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7L0N,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,Antibody,S309,S304,,,3,S,C,D,329;331;333;334;335;336;337;339;340;341;343;344;345;346;354;356;358;361;364;440;441;509,0,1,1,0,
7L2C,Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-terminal domain (NTD),2/10/2021,Antibody,Feb-51,,,,0,A,H,L,14;144;145;146;147;148;150;152;246;247;248;249;250;251;252;253;257,1,0,0,0,179;180;181;182;183;184
7L2C,Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-terminal domain (NTD),2/10/2021,Antibody,Feb-51,,,,1,B,C,D,144;145;146;147;148;150;152;246;247;248;249;250;251;252;253;257,1,0,0,0,178;179;180;181;182;183;184;185;211;212;213;214;215;216;217;218;219
7L2D,Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,Jan-87,,,,0,A,H,L,143;144;145;146;147;150;152;153;243;245;246;248;249;250;251;252;253;256;260,1,0,0,0,
7L2E,Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,18-Apr,,,,0,A,H,L,14;15;16;17;18;19;74;140;142;144;146;147;148;149;154;156;158;244;246;247;248;249;250;251;252;253;256,1,0,0,0,181;182;183
7L2E,Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,18-Apr,,,,1,B,G,J,14;15;16;17;18;19;74;140;142;144;146;147;148;149;154;156;158;244;246;247;248;249;250;251;252;253;256,1,0,0,0,181;182;183
7L2E,Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,18-Apr,,,,2,C,I,K,14;15;16;17;18;19;74;140;142;144;146;147;148;149;154;156;158;244;246;247;248;249;250;251;252;253;256,1,0,0,0,181;182;183
7L2F,Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,24-May,,,,0,A,H,L,14;15;16;142;144;146;147;152;154;156;158;161;246;248;249;250;251;252;253;254;256,1,0,0,0,70;71;72;73;74;75;76;180;181;182;183
7L2F,Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,24-May,,,,1,B,I,K,14;15;16;142;144;146;147;152;154;156;158;161;246;248;249;250;251;252;253;254;256,1,0,0,0,70;71;72;73;74;75;76;180;181;182;183
7L2F,Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,Antibody,24-May,,,,2,C,G,J,14;15;16;142;144;146;147;152;154;156;158;161;246;248;249;250;251;252;253;254;256,1,0,0,0,70;71;72;73;74;75;76;180;181;182;183
7L3N,SARS-CoV 2 Spike Protein bound to LY-CoV555,2/3/2021,Antibody,LY-CoV555,,,,0,"B,C",D,E,351;373;436;437;439;440;441;446;447;449;450;452;455;456;470;478;481;483;484;485;486;488;489;490;492;493;494;495;496,0,1,1,1,
7L56,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43,4/14/2021,Antibody,Feb-43,,,,0,A,H,L,417;447;449;452;455;456;470;475;483;484;485;486;488;489;490;492;493;494;496;498,0,1,1,0,
7L56,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43,4/14/2021,Antibody,Feb-43,,,,1,B,J,K,417;446;449;452;455;456;470;472;483;484;485;486;488;489;490;492;493;494;496;498,0,1,1,0,
7L56,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43,4/14/2021,Antibody,Feb-43,,,,2,C,F,G,417;447;449;452;455;456;470;472;483;484;485;486;488;489;490;492;493;494;496;498,0,1,1,0,
7L57,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15,4/14/2021,Antibody,15-Feb,,,,0,B,H,L,449;452;455;470;472;481;483;484;485;486;488;489;490;492;493;494;496;498,0,1,1,0,362;363;364;365;366;383;384;385;386;387;388;389;390
7L58,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4,4/14/2021,Antibody,H4,,,,0,B,H,L,447;449;452;455;456;472;475;476;483;484;485;486;487;489;490;492;493;494;496;498;500,0,1,1,0,
7L5B,Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD).,2/10/2021,Antibody,15-Feb,,,,0,A,H,L,446;447;449;452;455;456;470;472;476;478;483;484;485;486;487;488;489;490;492;493;494;496;498;505,0,1,1,0,362;363;364;365;366;383;384;385;386;387;388;389;390
7L7D,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895,9/1/2021,Antibody,AZD8895,,,,0,E,H,L,417;455;456;458;473;475;476;477;478;480;483;484;485;486;487;488;489;493,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,0,G,E,F,345;346;443;444;445;446;447;448;449;450;452;484;490;492;493;494;499,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,1,G,A,B,417;455;456;458;473;475;476;477;478;481;483;484;485;486;487;488;489;493,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,2,K,I,J,455;456;458;473;475;476;477;478;483;484;485;486;487;488;489;493,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,3,K,O,P,345;346;439;440;443;444;445;446;447;448;449;450;452;470;484;490;492;493;494;499,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,4,S,H,L,417;455;456;458;475;476;477;478;483;484;485;486;487;488;489;493,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,5,S,M,N,345;346;439;440;443;444;445;446;447;448;449;450;452;470;484;490;492;493;494;499,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,6,b,T,U,417;455;456;458;473;475;476;477;478;481;483;484;485;486;487;488;489;493,0,1,1,0,
7L7E,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,Antibody,AZD8895,AZD1061,,,7,b,C,D,345;346;439;440;443;444;445;446;447;448;449;450;452;470;484;490;492;493;494;499,0,1,1,0,
7LAA,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041,3/17/2021,Antibody,DH1041,,,,0,A,H,L,447;449;452;470;471;472;481;482;483;484;485;486;490;492;493;494;496,0,1,1,0,
7LAB,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052,3/10/2021,Antibody,DH1052,,,,0,A,T,S,27;28;29;30;32;59;61;64;66;67;68;69;97;98;186;187;210;211;212;213;214;215;217;218;219;264,1,0,0,0,70;71;72;73;74;75;76;77;78;79;144;145;146;147;148;149;150;151;152;153;154;155;156;157;158;159;160;161;162;163;164;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LAB,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052,3/10/2021,Antibody,DH1052,,,,1,B,Y,X,27;28;29;30;32;59;61;64;66;68;69;97;186;187;211;212;213;214;215;217;218;219;263;264,1,0,0,0,70;71;72;73;74;75;76;77;78;79;144;145;146;147;148;149;150;151;152;153;154;155;156;157;158;159;160;161;162;163;164;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LAB,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052,3/10/2021,Antibody,DH1052,,,,2,C,H,L,27;28;29;30;32;59;61;64;66;68;69;97;186;211;212;213;214;215;217;218;219;263;264,1,0,0,0,70;71;72;73;74;75;76;77;78;79;144;145;146;147;148;149;150;151;152;153;154;155;156;157;158;159;160;161;162;163;164;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LCN,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1,1/27/2021,Antibody,DH1050.1,,,,0,A,B,D,140;142;143;145;146;148;149;152;157;158;243;244;245,1,0,0,0,70;71;72;73;74;75;76;77;78;79;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LCN,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1,1/27/2021,Antibody,DH1050.1,,,,1,C,H,L,140;142;143;145;146;148;149;154;157;158;244;245,1,0,0,0,70;71;72;73;74;75;76;77;78;79;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LCN,Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1,1/27/2021,Antibody,DH1050.1,,,,2,K,M,S,140;142;143;145;146;148;149;151;152;154;157;243;244;245,1,0,0,0,70;71;72;73;74;75;76;77;78;79;173;174;175;176;177;178;179;180;181;182;183;184;185;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7LD1,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047,1/27/2021,Antibody,DH1047,,,,0,A,P,O,369;370;371;372;374;376;377;378;379;380;383;384;387;403;404;405;406;408;409;411;414;415;416;417;419;420;430;433;435;501;502;503;504;505;508;510,0,1,1,0,455;456;457;458;459;460;461;516;517;518;519;520;521
7LD1,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047,1/27/2021,Antibody,DH1047,,,,1,B,H,L,369;370;372;374;375;376;377;378;379;380;383;384;386;387;404;405;407;408;411;412;432;435;502;503;504;506;508,0,1,1,0,455;456;457;458;459;460;461;516;517;518;519;520;521
7LD1,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047,1/27/2021,Antibody,DH1047,,,,2,C,M,N,369;370;372;374;375;376;377;378;379;380;383;384;404;405;407;408;410;411;412;435;502;503;504;505;508,0,1,1,0,455;456;457;458;459;460;461;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490;516;517;518;519;520;521
7LJR,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,3/31/2021,Antibody,DH1043,,,,0,A,S,T,444;446;447;449;450;452;453;456;470;472;473;475;476;478;479;480;481;483;484;485;486;487;488;489;490;491;492;493;494;496,0,1,1,0,
7LM8,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,3/31/2021,Antibody,CV38-142,COVA1-16,,,0,A,H,L,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;432,0,1,0,0,
7LM8,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,3/31/2021,Antibody,CV38-142,COVA1-16,,,1,A,M,N,343;345;346;371;373;436;438;440;441;443;444;445;448;450;499;509,0,1,1,0,
7LOP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,Antibody,CV05-163,CR3022,,,0,A,B,C,369;370;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;407;408;411;412;414;428;430;432;515;517,0,1,0,0,
7LOP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,Antibody,CV05-163,CR3022,,,1,A,H,L,351;444;446;447;449;452;455;456;470;472;482;483;484;485;486;489;490;491;492;493;494;496;498,0,1,1,0,
7LOP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,Antibody,CV05-163,CR3022,,,2,Z,W,V,369;370;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;407;408;411;412;414;428;430;432;515;517,0,1,0,0,
7LOP,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,Antibody,CV05-163,CR3022,,,3,Z,X,Y,351;444;446;447;449;452;455;456;470;472;482;483;484;485;486;489;490;491;492;493;494;496;498;500,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,0,A,H,L,417;455;456;475;476;477;478;479;480;481;483;484;485;486;487;488;489;490;493;494,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,1,A,P,Q,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;504,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,2,B,T,U,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;430;504,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,3,B,C,D,417;455;456;475;476;477;478;479;481;483;484;485;486;487;488;489;490;493;494,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,4,E,y,z,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;504,0,1,1,0,
7LQ7,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,Antibody,CV503,COVA1-16,,,5,E,F,G,455;456;475;476;477;478;479;480;481;483;484;485;486;487;488;489;490;493;494,0,1,1,0,
7LQV,Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,Antibody,8-Apr,,,,0,A,H,L,14;142;144;146;147;148;149;151;152;153;154;156;157;158;246;248;249;253,1,0,0,0,178;179;180;181;182;183;184;185
7LQV,Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,Antibody,8-Apr,,,,1,B,W,X,14;142;144;146;147;149;152;154;156;158;161;246;249;253,1,0,0,0,178;179;180;181;182;183;184;185
7LQV,Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,Antibody,8-Apr,,,,2,C,Y,Z,14;16;142;144;146;147;148;152;154;156;157;158;161;246;248;249;250;251;252;253;254;256,1,0,0,0,178;179;180;181;182;183;184;185
7LQW,Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,Antibody,17-Feb,,,,0,C,H,L,14;16;17;18;19;20;21;76;77;78;79;138;140;144;154;156;158;244;246;247;254;255,1,0,0,0,35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;178;179;180;181;182;183;184;185
7LRS,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,Antibody,A23-58.1,,,,0,C,D,E,417;455;456;473;475;476;477;478;480;483;484;485;486;487;488;489;490;493,0,1,1,0,
7LRT,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,Antibody,A23-58.1,,,,0,A,H,L,455;456;473;475;476;478;479;480;483;484;485;486;487;488;489;493,0,1,1,0,
7LRT,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,Antibody,A23-58.1,,,,1,B,F,G,455;456;473;475;476;477;478;479;480;483;484;485;486;487;489;493,0,1,1,0,
7LRT,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,Antibody,A23-58.1,,,,2,C,D,E,455;456;473;475;476;477;478;479;480;483;484;485;486;487;488;489;493,0,1,1,0,
7LS9,Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/17/2021,Antibody,Jan-57,,,,0,A,H,L,346;349;351;444;445;446;447;448;449;450;452;470;484;490;492;493;494;496;498;500,0,1,1,0,
7LS9,Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/17/2021,Antibody,Jan-57,,,,1,B,D,F,349;351;444;445;446;447;448;449;450;452;470;484;485;490;492;493;494;496;498;500,0,1,1,0,
7LS9,Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/17/2021,Antibody,Jan-57,,,,2,C,E,G,351;444;445;446;447;448;449;450;452;470;484;485;490;492;493;494;496;498;500,0,1,1,0,
7LSS,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,3/17/2021,Antibody,7-Feb,,,,0,B,H,L,345;346;437;439;440;441;443;444;445;446;448;450;498;499;500;506,0,1,1,0,
7LXW,SARS-CoV-2 S/S2M11/S2X333 Local Refinement,4/14/2021,Antibody,S2X333,,,,0,A,H,L,14;16;17;18;140;142;143;144;146;147;148;152;154;156;158;244;246;249;250;251,1,0,0,0,20;21;22;23;24;25;26;27;28;29;30;31;32;33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;60;61;62;63;64;65;66;70;71;72;73;74;75;76;86;87;88;89;90;91;92;93;94;95;96;97;98;99;123;124;125;164;165;166;167;168;169;170;171;172;173;174;175;176;177;178;179;180;181;182;183;184;185;186;187;188;189;190;191;192;193;194;195;196;197;198;199;200;201;202;203;204;205;206;207;208;209;210;211;212;213;214;215;216;217;218;219;220;221;222;223;224;225;226;227;228;229;230;231;232;233;234
7LXX,SARS-CoV-2 S/S2M11/S2L28 Local Refinement,4/14/2021,Antibody,S2L28,,,,0,A,H,L,14;16;17;19;20;142;144;146;155;156;158;246;248;250;251;252;253;254;255;256;257,1,0,0,0,25;26;27;28;29;30;31;32;33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;60;61;62;71;72;73;74;75;86;87;88;89;90;91;92;93;94;95;96;97;108;109;110;111;112;113;114;165;166;167;168;169;170;171;172;173;174;175;176;177;178;179;180;181;182;183;184;185;186;187;188;189;190;191;192;193;194;195;196;197;198;199;200;201;202;203;204;205;206;207;208;209;210;211;212;213;214;215;216;217;218;219;220;221;222;223;224;225;226;227;228;229;230;231;232;233;234;235
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,0,A,E,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,1,A,H,L,14;16;17;18;140;142;143;144;146;147;148;152;154;156;158;244;246;249,1,0,0,0,19;20;21;22;23;24;25;26;67;68;69;70;71;72;73;74;75;76;177;178;179;180;181;182;183;184;185;186;251;252;253;254;255;256;257;258;259;260;261;262;263
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,2,B,F,C,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,3,B,G,I,14;16;17;18;140;142;143;144;146;147;148;152;154;156;158;244;246;249,1,0,0,0,19;20;21;22;23;24;25;26;67;68;69;70;71;72;73;74;75;76;177;178;179;180;181;182;183;184;185;186;251;252;253;254;255;256;257;258;259;260;261;262;263
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,4,J,N,O,14;16;17;18;140;142;143;144;146;147;148;152;154;156;158;244;246;249,1,0,0,0,19;20;21;22;23;24;25;26;67;68;69;70;71;72;73;74;75;76;177;178;179;180;181;182;183;184;185;186;251;252;253;254;255;256;257;258;259;260;261;262;263
7LXY,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,Antibody,S2M11,S2X333,,,5,J,M,K,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,0,A,H,J,16;17;19;20;142;144;146;155;156;158;246;248;250;251;252;253;254;255;256;257,1,0,0,0,70;71;72;73;74;75;76;183;184;185
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,1,A,E,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,2,B,G,I,16;17;19;20;142;144;146;155;156;158;246;248;250;251;252;253;254;255;256;257,1,0,0,0,70;71;72;73;74;75;76;183;184;185
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,3,B,F,C,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,4,K,N,O,16;17;19;20;142;144;146;155;156;158;246;248;250;251;252;253;254;255;256;257,1,0,0,0,70;71;72;73;74;75;76;183;184;185
7LXZ,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,Antibody,S2M11,S2L28,,,5,K,M,L,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7LY0,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,4/14/2021,Antibody,S2M28,,,,0,A,H,L,14;16;17;18;20;21;75;77;140;142;144;146;147;148;153;155;156;158;246;247;249;250;251;252;253;254;255,1,0,0,0,22;23;24;25;26;27;28;29;30;31;32;33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;60;61;62;63;64;65;66;67;71;72;73;74;87;88;89;90;164;165;166;167;168;169;170;171;172;173;177;178;179;180;181;182;183;184;185;186;193;194;195;196;197;198;199;200;201;202;203;204;205;206;207;208;209;210;211;212;213;214;215;216;217;218;219;220;221;222;223;224;225;226;227;228;229;230;231;232;233;234;256;257;258;259;260;261;262
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,0,A,H,L,14;16;17;18;20;77;142;144;146;147;148;153;155;156;158;246;247;249;250;251;252;253;254;255,1,0,0,0,21;22;23;24;25;26;68;69;70;71;72;73;74;75;177;178;179;180;181;182;183;184;185;186;256;257;258;259;260;261;262
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,1,A,E,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,2,B,F,C,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,3,B,G,I,14;16;17;18;20;77;142;144;146;147;148;153;155;156;158;246;247;249;250;251;252;253;254;255,1,0,0,0,21;22;23;24;25;26;68;69;70;71;72;73;74;75;177;178;179;180;181;182;183;184;185;186;256;257;258;259;260;261;262
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,4,J,N,O,14;16;17;18;20;77;142;144;146;147;148;153;155;156;158;246;247;249;250;251;252;253;254;255,1,0,0,0,21;22;23;24;25;26;68;69;70;71;72;73;74;75;177;178;179;180;181;182;183;184;185;186;256;257;258;259;260;261;262
7LY2,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,Antibody,S2M11,S2M28,,,5,J,M,K,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7LY3,Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab,4/14/2021,Antibody,S2M28,,,,0,A,D,C,14;16;17;18;20;21;75;77;140;142;144;146;147;148;153;155;156;158;246;249;250;251;252;253;254;256;257,1,0,0,0,72;73;179;180;181;182;183;184;185;186
7LY3,Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab,4/14/2021,Antibody,S2M28,,,,1,B,F,E,14;16;17;18;20;21;74;75;77;140;142;144;146;147;148;153;155;156;158;246;249;250;251;252;253;254;256;257,1,0,0,0,71;72;73;179;180;181;182;183;184;185;186
7M3I,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab",5/12/2021,Antibody,CV2-75,,,,0,C,A,B,369;370;373;374;375;376;377;378;379;380;382;383;384;385;386;404;405;408;411;412;413;437;502;503;504;506;508,0,1,1,0,
7M3I,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab",5/12/2021,Antibody,CV2-75,,,,1,R,H,L,369;370;373;374;375;376;377;378;379;380;382;383;384;385;386;404;405;408;411;412;413;437;502;503;504;506;508,0,1,1,0,
7M42,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,7/28/2021,Antibody,REGN10989,REGN10985,,,0,E,D,C,369;372;375;376;377;378;379;383;384;385;404;405;407;408;411;414;416;435;437;502;503;504;506;508,0,1,1,0,
7M42,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,7/28/2021,Antibody,REGN10989,REGN10985,,,1,E,B,A,447;449;452;455;456;470;472;475;484;485;486;487;489;490;492;493;494;496;498,0,1,1,0,
7M6D,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,5/5/2021,Antibody,BG4-25,CR3022,,,0,C,A,B,369;370;374;376;377;378;379;380;381;382;383;384;385;386;389;390;392;407;408;411;412;414;426;428;430;432;515;516;517;519,0,1,0,0,
7M6D,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,5/5/2021,Antibody,BG4-25,CR3022,,,1,C,H,L,403;405;415;416;417;419;420;421;447;453;455;456;457;458;460;473;474;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7M6E,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19",5/5/2021,Antibody,BG10-19,,,,0,A,H,L,338;339;342;343;345;346;367;368;371;372;373;374;377;434;436;438;440;441;442;444;445;448;450;499;509,0,1,1,0,
7M6E,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19",5/5/2021,Antibody,BG10-19,,,,1,B,F,G,338;339;342;343;345;346;367;368;371;372;373;374;377;434;436;438;440;441;442;444;445;448;450;499;509,0,1,1,0,
7M6E,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19",5/5/2021,Antibody,BG10-19,,,,2,E,D,C,338;339;342;343;345;346;367;368;371;372;373;374;434;436;438;440;441;442;444;445;448;450;499;509,0,1,1,0,
7M6F,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG1-22",5/5/2021,Antibody,BG1-22,,,,0,A,H,L,403;404;405;408;415;416;417;419;420;421;424;456;460;473;475;476;477;478;486;487;489;496;498;500;501;502;503;504;505,0,1,1,0,
7M6F,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG1-22",5/5/2021,Antibody,BG1-22,,,,1,E,C,D,403;404;405;408;409;415;416;417;419;420;421;456;458;460;473;475;476;477;478;486;487;489;496;501;502;503;504;505,0,1,1,0,
7M6G,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG7-15",5/5/2021,Antibody,BG7-15,,,,0,B,R,S,346;437;439;440;443;444;445;446;447;448;449;450;451;452;493;494;499;500;506,0,1,1,0,455;456;457;458;459;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486
7M6G,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG7-15",5/5/2021,Antibody,BG7-15,,,,1,C,H,L,346;437;439;440;443;444;445;446;447;449;450;452;492;494;496;499;500;506,0,1,1,0,455;456;457;458;459;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486
7M6H,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20",5/5/2021,Antibody,BG7-20,,,,0,A,E,G,351;417;447;449;452;453;455;456;470;472;475;478;483;484;485;486;487;489;490;491;492;493;494;496;498;500;501;505,0,1,1,0,
7M6H,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20",5/5/2021,Antibody,BG7-20,,,,1,"B,C",D,F,375;376;378;411;413;414;417;447;449;452;455;456;470;472;473;475;476;478;483;484;485;486;488;489;490;492;493;494;496;498,0,1,1,1,
7M6I,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG1-24",5/5/2021,Antibody,BG1-24,,,,0,A,M,N,351;449;452;455;470;472;473;479;481;482;483;484;485;486;487;488;489;490;492;493;494;496,0,1,1,0,445;446
7M6I,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG1-24",5/5/2021,Antibody,BG1-24,,,,1,"B,C",H,L,351;372;375;376;407;408;411;414;435;449;452;455;456;468;470;472;473;477;479;482;483;484;485;486;488;489;490;491;492;493;494,0,1,1,1,445;446;502
7M71,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,5/26/2021,Antibody,5A6,,,,0,"A,B",H,L,369;375;377;378;404;447;449;452;455;456;470;471;472;481;482;483;484;485;486;487;489;490;492;493;494;496;503,0,1,1,1,
7M7B,SARS-CoV-2 Spike:Fab 3D11 complex focused refinement,5/26/2021,Antibody,3D11,,,,0,A,H,L,366;369;370;372;374;375;376;377;378;379;383;384;385;407;408;411;435;503,0,1,1,0,
7M7W,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,Antibody,S2X259,S2H97,,,0,R,E,F,355;357;393;394;396;426;427;428;429;459;460;462;463;464;466;468;514;516;518;519;520;521,0,1,1,0,
7M7W,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,Antibody,S2X259,S2H97,,,1,R,H,L,369;370;372;374;375;376;377;378;379;380;383;384;385;386;404;405;407;408;411;413;416;432;433;435;437;439;500;502;503;504;505;506;508,0,1,1,0,
7M7W,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,Antibody,S2X259,S2H97,,,2,S,C,D,355;357;393;394;396;426;427;428;429;459;462;463;464;466;514;516;518;519;520;521;523,0,1,1,0,
7M7W,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,Antibody,S2X259,S2H97,,,3,S,A,B,369;370;372;374;375;376;377;378;379;380;383;384;385;386;404;405;407;408;411;413;416;433;435;437;439;502;503;504;506;508,0,1,1,0,
7M8J,SARS-CoV-2 S-NTD + Fab CM25,5/19/2021,Antibody,CM25,,,,0,A,H,L,144;145;146;147;148;150;152;153;246;247;248;249;251;252;255,1,0,0,0,33;34;35;36;37;38;39;40;41;42;43;44;45;46;47;48;49;50;51;52;53;54;55;56;57;58;59;220;221;222;223;224;225
7MF1,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,5/12/2021,Antibody,47D1,,,,0,A,H,L,351;447;449;450;452;470;472;480;481;482;483;484;485;490;491;492;493;494,0,1,1,0,
7MJJ,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1),5/12/2021,Antibody,ab1,,,,0,A,D,E,403;405;408;415;416;417;419;420;421;455;456;457;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7MJJ,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1),5/12/2021,Antibody,ab1,,,,1,B,F,G,403;405;408;415;417;419;420;421;455;456;457;458;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7MJK,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2),5/12/2021,Antibody,ab1,,,,0,A,D,E,403;405;408;415;416;417;420;421;455;456;457;458;460;473;475;476;477;478;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7MJK,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2),5/12/2021,Antibody,ab1,,,,1,B,F,G,403;405;408;415;416;417;420;421;455;456;457;458;460;473;475;476;477;478;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7MJK,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2),5/12/2021,Antibody,ab1,,,,2,C,H,I,403;405;408;415;416;417;420;421;455;456;457;458;459;460;473;475;476;477;478;486;487;489;490;493;495;496;498;501;502;504;505,0,1,1,0,
7MJL,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused refinement of RBD and Fab ab1),5/12/2021,Antibody,ab1,,,,0,A,H,L,403;405;406;408;415;416;417;419;420;421;455;456;457;458;459;460;473;475;476;477;478;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7MKL,SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation),5/12/2021,Antibody,SARS2-38,,,,0,A,H,L,345;440;441;443;444;445;446;447;448;449;450;499,0,1,1,0,
7MKM,SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement),5/12/2021,Antibody,SARS2-38,,,,0,A,H,L,345;440;441;443;444;445;446;447;448;449;450;499,0,1,1,0,
7MLZ,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,7/28/2021,Antibody,B1-182.1,,,,0,A,H,L,417;421;453;455;456;458;473;474;475;476;477;478;479;480;481;483;485;486;487;488;489;490;493,0,1,1,0,
7MM0,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,7/28/2021,Antibody,B1-182.1,,,,0,A,H,L,417;421;453;455;456;458;473;474;475;476;477;478;479;480;481;483;485;486;487;488;489;493,0,1,1,0,
7MMO,LY-CoV1404 neutralizing antibody against SARS-CoV-2,5/12/2021,Antibody,LY-CoV1404,,,,0,C,A,B,345;346;439;440;441;442;443;444;445;446;448;450;498;499;500;502;503;505;506,0,1,1,0,
7MMO,LY-CoV1404 neutralizing antibody against SARS-CoV-2,5/12/2021,Antibody,LY-CoV1404,,,,1,F,D,E,345;439;440;441;442;443;444;445;446;447;448;450;498;499;500;502;505;506;509,0,1,1,0,364;365;366;367;368;369;370;371;385;386;387;388
7MZF,SARS-CoV-2 receptor binding domain bound to Fab PDI 37,10/6/2021,Antibody,PDI 37,,,,0,A,H,L,403;405;406;408;415;416;417;419;420;421;447;453;455;456;458;459;460;473;474;475;476;477;478;486;487;489;493;496;498;500;501;502;504;505,0,1,1,0,
7MZG,SARS-CoV-2 receptor binding domain bound to Fab PDI 42,10/6/2021,Antibody,PDI 42,,,,0,A,H,L,403;405;406;409;415;416;417;420;421;447;449;455;456;458;459;460;473;475;476;477;478;484;486;487;489;490;493;494;496;498;500;501;502;504;505,0,1,1,0,445;446
7MZH,SARS-CoV-2 receptor binding domain bound to Fab WCSL 119,10/6/2021,Antibody,WCSL 119,,,,0,A,B,C,417;447;449;455;456;472;473;475;476;477;478;481;482;483;484;485;486;487;489;493;494;496,0,1,1,0,
7MZH,SARS-CoV-2 receptor binding domain bound to Fab WCSL 119,10/6/2021,Antibody,WCSL 119,,,,1,E,H,L,417;447;449;455;456;472;473;475;476;477;478;481;482;483;484;485;486;487;489;493;496,0,1,1,0,
7MZI,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129,10/6/2021,Antibody,WCSL 129,,,,0,A,H,L,403;405;406;409;415;416;417;420;421;453;455;456;458;459;473;475;476;477;478;483;485;486;487;489;493;505,0,1,1,0,
7MZJ,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,Antibody,WCSL 129,PDI 93,,,0,A,F,E,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;477;478;483;485;486;487;489;493;504;505,0,1,1,0,
7MZJ,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,Antibody,WCSL 129,PDI 93,,,1,A,H,L,345;346;349;351;352;440;441;442;443;444;445;446;447;448;449;450;451;452;468;470;472;484;490;493;494;496;499,0,1,1,0,
7MZJ,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,Antibody,WCSL 129,PDI 93,,,2,B,C,D,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;477;478;483;485;486;487;489;490;493;505,0,1,1,0,
7MZJ,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,Antibody,WCSL 129,PDI 93,,,3,B,N,M,345;346;349;351;352;440;441;442;444;445;446;447;448;449;450;451;452;466;468;470;472;484;490;493;494;496;499,0,1,1,0,
7MZK,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,Antibody,WCSL 129,PDI 96,,,0,A,H,L,343;373;436;438;439;440;441;443;444;445;446;448;449;498;499;500;509,0,1,1,0,
7MZK,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,Antibody,WCSL 129,PDI 96,,,1,A,F,E,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;477;478;484;485;486;487;489;493;505,0,1,1,0,
7MZK,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,Antibody,WCSL 129,PDI 96,,,2,B,C,D,403;405;406;409;416;417;420;421;453;455;456;458;473;475;476;477;478;485;486;487;489;493;505,0,1,1,0,
7MZK,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,Antibody,WCSL 129,PDI 96,,,3,B,N,M,343;371;373;436;438;439;440;441;443;444;445;446;448;449;498;499;500;509,0,1,1,0,
7MZL,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,10/6/2021,Antibody,PDI 210,,,,0,A,H,L,403;417;421;447;449;453;455;456;457;458;473;475;476;477;478;484;486;487;489;490;493;494;495;496;501;502;505,0,1,1,0,518;519
7MZM,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,10/6/2021,Antibody,PDI 215,,,,0,A,H,L,346;347;348;349;351;352;354;450;452;468,0,1,1,0,
7MZN,SARS-CoV-2 receptor binding domain bound to Fab PDI 231,10/6/2021,Antibody,PDI 231,,,,0,A,H,L,403;405;406;415;416;417;420;421;453;455;456;458;460;473;475;476;477;478;484;485;486;487;489;490;493;494;496;498;501;502;504;505,0,1,1,0,
7N3I,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098,8/4/2021,Antibody,C098,,,,0,C,H,L,403;405;415;416;417;419;420;421;447;453;455;456;458;459;460;473;475;476;477;484;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,519
7N4I,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2057.,10/6/2021,Antibody,WRAIR-2057,,,,0,C,H,L,353;355;357;396;426;457;458;459;462;463;464;465;466;467;468;469;471;474;479;480;481;482;491,0,1,1,0,
7N4J,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2173.,10/6/2021,Antibody,WRAIR-2173,,,,0,A,H,L,403;444;445;446;447;449;450;452;453;455;470;475;483;484;486;488;489;490;492;493;494;496;498;500;501;505,0,1,1,0,
7N4L,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.,11/10/2021,Antibody,WRAIR-2125,,,,0,A,H,L,417;420;453;455;456;473;475;476;477;484;485;486;487;489;493;496;505,0,1,1,0,
7N4M,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2151.,11/10/2021,Antibody,WRAIR-2151,,,,0,A,H,L,366;369;370;372;374;375;376;377;378;379;380;383;384;385;387;388;407;408;411;435;437,0,1,0,0,
7N5H,Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein,11/3/2021,Antibody,Feb-36,,,,0,A,H,L,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;427;428;429;433;504,0,1,1,0,
7N5H,Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein,11/3/2021,Antibody,Feb-36,,,,1,B,E,F,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;433;504,0,1,1,0,
7N5H,Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein,11/3/2021,Antibody,Feb-36,,,,2,C,J,K,369;372;374;377;378;379;380;381;383;384;385;405;408;409;411;412;413;414;415;416;419;427;428;429;433;504,0,1,1,0,
7N62,SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction),8/4/2021,Antibody,C12C9,,,,0,A,H,L,14;16;142;144;145;146;147;153;155;157;158;246;248;249;251;252;253;254,1,0,0,0,
7N64,SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction),8/4/2021,Antibody,G32R7,,,,0,"A,B",H,L,164;169;337;339;340;341;343;344;345;346;347;348;352;354;356;399;401;441;442;450;451;468,1,1,1,1,291;292;293;294;295;296;297;298;299;300;301;302;303;304;305;306;307;308;309;310;311;312;313;314;315;316;317;318;319;320;321;322;323;324;325;326;327;328;329;330
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,0,A,E,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,1,A,C,B,28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;234;236;237;239;267;269;270;271;272,1,0,0,0,68;69;70;71;72;73;74;75;76;77;78;79;80;138;139;140;141;142;143;144;145;146;147;148;149;150;151;152;153;154;155;156;157;177;178;179;180;181;182;183;184;185;243;244;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262;263
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,2,F,J,I,28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;234;236;237;239;267;269;270;271;272,1,0,0,0,68;69;70;71;72;73;74;75;76;77;78;79;80;138;139;140;141;142;143;144;145;146;147;148;149;150;151;152;153;154;155;156;157;177;178;179;180;181;182;183;184;185;243;244;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262;263
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,3,F,H,G,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,4,K,O,N,28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;234;236;237;239;267;269;270;271;272,1,0,0,0,68;69;70;71;72;73;74;75;76;77;78;79;80;138;139;140;141;142;143;144;145;146;147;148;149;150;151;152;153;154;155;156;157;177;178;179;180;181;182;183;184;185;243;244;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262;263
7N8H,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,Antibody,S2M11,S2L20,,,5,K,M,L,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,
7N8I,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20),7/14/2021,Antibody,S2L20,,,,0,A,H,L,28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;234;236;237;267;269;271;272,1,0,0,0,68;69;70;71;72;73;74;75;76;77;78;79;80;138;139;140;141;142;143;144;145;146;147;148;149;150;151;152;153;154;155;156;157;177;178;179;180;181;182;183;184;185;244;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262;263
7ND3,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,3/3/2021,Antibody,COVOX-40,,,,0,B,H,L,403;405;415;416;417;419;420;421;447;449;453;456;457;458;459;460;473;474;475;476;477;478;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7ND4,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab,3/3/2021,Antibody,COVOX-88,,,,0,A,D,E,403;405;406;409;416;417;455;456;472;473;475;476;484;485;486;487;489;493;496;502;504;505,0,1,1,0,
7ND4,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab,3/3/2021,Antibody,COVOX-88,,,,1,B,F,G,403;405;406;409;416;417;455;456;472;473;475;476;478;480;484;485;486;487;489;490;493;496;505,0,1,1,0,
7ND4,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab,3/3/2021,Antibody,COVOX-88,,,,2,C,H,L,403;405;406;409;416;417;453;455;456;472;473;475;476;484;485;486;487;489;490;493;496;502;505,0,1,1,0,
7ND5,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,3/3/2021,Antibody,COVOX-150,,,,0,B,H,L,403;405;406;408;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;490;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7ND6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,3/3/2021,Antibody,COVOX-40,,,,0,B,H,L,403;405;406;408;409;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7ND7,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,Antibody,COVOX-316,,,,0,A,H,L,447;449;452;453;455;456;470;475;483;484;485;486;487;488;489;490;492;493;494;496;498,0,1,1,0,
7ND7,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,Antibody,COVOX-316,,,,1,B,F,G,447;449;452;453;455;456;470;475;483;484;485;486;487;488;489;490;492;493;494;496;498,0,1,1,0,
7ND7,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,Antibody,COVOX-316,,,,2,C,J,K,447;449;452;453;455;456;470;475;483;484;485;486;487;488;489;490;492;493;494;496;498,0,1,1,0,
7ND8,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab,3/3/2021,Antibody,COVOX-384,,,,0,B,H,L,446;447;449;452;455;456;470;472;475;478;483;484;485;486;488;489;490;492;493;494,0,1,1,0,
7ND9,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab,3/3/2021,Antibody,COVOX-253H55L,,,,0,B,H,L,417;421;453;455;456;458;473;475;476;477;478;479;484;485;486;487;488;489;490;493,0,1,1,0,
7NDA,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab,3/3/2021,Antibody,COVOX-253H55L,,,,0,"A,C",H,L,333;417;455;456;458;473;475;476;477;478;484;485;486;487;488;489;490;493;527,0,1,1,1,
7NDB,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab,3/3/2021,Antibody,COVOX-253H165L,,,,0,B,H,L,417;455;456;473;475;476;477;478;485;486;487;488;489;493,0,1,1,0,
7NDC,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,0,A,F,G,14;144;146;147;148;153;155;157;158;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NDC,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,1,B,H,L,14;144;146;147;148;153;155;157;158;251;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NDC,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,2,C,D,E,14;144;146;147;148;153;155;157;158;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NDD,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,0,A,F,G,14;144;146;147;148;153;155;157;158;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NDD,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,1,B,H,L,14;144;146;147;148;153;155;157;158;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NDD,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159,3/3/2021,Antibody,COVOX-159,,,,2,C,D,E,14;144;146;147;148;153;155;157;158;252;254,1,0,0,0,70;71;72;73;74;75;76;179;180;181;182;183;184
7NEG,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,3/3/2021,Antibody,COVOX-269,,,,0,E,H,L,403;405;406;415;416;417;420;421;447;453;455;456;458;460;473;474;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7NEH,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,3/3/2021,Antibody,COVOX-269,,,,0,E,H,L,403;405;406;408;415;416;417;420;421;447;449;453;455;456;458;459;460;473;474;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7NP1,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,11/17/2021,Antibody,ION-360,,,,0,A,H,L,405;408;415;417;420;421;455;456;458;459;460;473;475;476;477;478;486;487;489;493;496;498;502;504;505,0,1,1,0,362;363;364;365;385;386;387;388;389
7NP1,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,11/17/2021,Antibody,ION-360,,,,1,B,I,M,405;415;417;420;421;455;456;458;459;460;473;475;476;477;478;486;487;489;493;496;498;502;504;505,0,1,1,0,364;365;366;367;385;386;387;388;389;390;391
7NP1,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,11/17/2021,Antibody,ION-360,,,,2,C,J,N,403;405;408;415;416;417;420;421;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,370;517;518;519;520;521;522
7NP1,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,11/17/2021,Antibody,ION-360,,,,3,D,K,O,403;405;408;415;416;417;420;421;455;456;458;459;460;473;475;476;477;486;487;489;493;496;498;501;502;504;505,0,1,1,0,370;517;518;519;520;521;522
7NTC,Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab,4/28/2021,Antibody,P008_056,,,,0,C,H,L,69;71;75;97;98;99;123;124;144;145;146;147;150;151;152;153;178;180;182;185;186;188;213;214;245;247;248;249;257;259;260;261;262,1,0,0,0,
7NX6,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7NX6,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,
7NX7,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7NX7,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7NX8,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7NX8,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,A,B,403;405;408;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7NX9,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7NX9,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7NXA,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;457;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7NXA,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7NXB,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,0,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;459;460;473;475;476;477;486;487;489;493;495;496;498;500;501;502;504;505,0,1,1,0,
7NXB,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,Antibody,COVOX-222,EY6A,,,1,E,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517,0,1,0,0,
7OR9,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,7/7/2021,Antibody,COVOX-222,COVOX-278,,,0,E,H,L,345;346;349;351;352;441;442;443;444;445;446;447;448;449;450;451;452;470;482;484;490;492;494;499,0,1,1,0,
7OR9,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,7/7/2021,Antibody,COVOX-222,COVOX-278,,,1,E,A,B,403;405;408;415;416;417;420;421;447;453;455;456;457;458;459;460;473;475;476;477;486;487;489;493;495;496;498;501;502;503;504;505,0,1,1,0,
7ORA,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-45,COVOX-253,,,0,C,H,L,417;453;455;456;473;475;476;477;478;479;484;485;486;487;488;489;493,0,1,1,0,
7ORA,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-45,COVOX-253,,,1,C,D,E,331;337;346;348;353;354;355;356;357;359;360;394;396;424;426;428;462;463;464;465;466;468;514;516;518;519;520;521;523,0,1,1,0,
7ORA,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-45,COVOX-253,,,2,R,A,B,331;337;346;348;353;354;355;356;357;359;360;394;396;424;426;428;462;463;464;465;466;468;514;516;518;519;520;521;523,0,1,1,0,
7ORA,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-45,COVOX-253,,,3,R,F,G,417;420;421;455;456;473;475;476;477;478;479;484;485;486;487;488;489;493,0,1,1,0,
7ORB,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-75,COVOX-253,,,0,R,H,L,417;421;453;455;456;473;475;476;477;478;485;486;487;488;489;490;493,0,1,1,0,
7ORB,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-75,COVOX-253,,,1,R,A,B,346;442;444;445;446;447;448;449;450;452;455;484;490;493;494;496;499;500,0,1,1,0,
7ORB,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-75,COVOX-253,,,2,X,E,F,346;442;444;445;446;447;448;449;450;452;455;484;490;493;494;496;499;500,0,1,1,0,
7ORB,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,Antibody,COVOX-75,COVOX-253,,,3,X,C,D,417;421;453;455;456;473;475;476;477;478;484;485;486;487;488;489;490;493,0,1,1,0,
7P40,P5C3 is a potent fab neutralizer,10/13/2021,Antibody,P5C3,,,,0,A,F,B,417;449;453;455;456;473;475;476;477;478;479;481;483;484;485;486;487;489;490;493;494;496,0,1,1,0,
7P40,P5C3 is a potent fab neutralizer,10/13/2021,Antibody,P5C3,,,,1,E,C,D,417;449;453;455;456;473;475;476;477;478;481;483;484;485;486;487;489;490;493;494;496,0,1,1,0,
7P40,P5C3 is a potent fab neutralizer,10/13/2021,Antibody,P5C3,,,,2,G,I,H,417;453;455;456;473;475;476;477;478;480;481;483;485;486;487;488;489;490;493;496,0,1,1,0,
7PHG,MaP OF P5C3RBD Interface,10/13/2021,Antibody,P5C3,,,,0,A,H,L,417;421;453;455;456;458;473;474;475;476;477;478;480;481;483;484;485;486;487;488;489;490;493;496,0,1,1,0,
7R6W,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,7/21/2021,Antibody,S2X35,S309,,,0,R,A,B,334;335;337;339;340;341;343;344;345;354;356;358;361;440;441;444,0,1,1,0,
7R6W,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,7/21/2021,Antibody,S2X35,S309,,,1,R,H,L,369;370;372;374;375;376;377;378;379;380;383;384;403;404;405;407;408;411;432;433;435;437;496;498;501;502;503;504;505;508,0,1,1,0,
7R6X,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,Antibody,S2E12,S309,S304,,0,R,A,B,331;332;334;335;337;339;340;341;343;344;345;346;354;356;358;361;362;440;441;444,0,1,1,0,
7R6X,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,Antibody,S2E12,S309,S304,,1,R,H,L,366;369;370;377;378;379;380;381;382;383;384;385;386;388;389;390;411;412;413;414;427;428;429;430;517;528,0,1,0,0,
7R6X,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,Antibody,S2E12,S309,S304,,2,R,C,D,417;455;456;473;475;476;477;478;479;480;483;484;485;486;487;488;489;493,0,1,1,0,
7R7N,SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of the RBD and S2D106),7/21/2021,Antibody,S2D106,,,,0,E,H,L,351;417;446;447;449;452;455;456;470;472;475;478;482;483;484;485;486;488;489;490;491;492;493;494,0,1,1,0,518;519;520;521
7R8L,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,8/4/2021,Antibody,C099,CR3022,,,0,E,C,D,369;370;374;376;377;378;379;380;381;382;383;384;385;386;389;390;407;408;411;428;430;432;515;517,0,1,0,0,519
7R8L,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,8/4/2021,Antibody,C099,CR3022,,,1,E,H,L,403;405;415;416;417;420;421;447;449;453;455;456;458;459;460;473;475;476;477;478;486;487;489;493;495;496;498;500;501;502;503;504;505,0,1,1,0,519
7R8M,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032,8/4/2021,Antibody,C032,,,,0,B,H,L,337;339;340;343;344;345;346;373;437;439;440;441;442;443;444;445;448;450;451;499;500;509,0,1,1,0,
7R8M,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032,8/4/2021,Antibody,C032,,,,1,C,D,E,337;339;340;343;344;345;346;437;439;440;441;443;449;450;497;498,0,1,1,0,444;445;446;447;448;455;456;457;458;459;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;499;500;501;502
7R8N,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051,8/4/2021,Antibody,C051,,,,0,A,H,L,405;417;447;449;452;455;456;470;472;475;476;484;485;486;487;489;490;491;492;493;494;496;498,0,1,1,0,
7R8N,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051,8/4/2021,Antibody,C051,,,,1,B,O,P,405;417;447;449;452;453;455;456;470;472;475;476;484;485;486;487;489;490;491;492;493;494;496;498,0,1,1,0,
7R8N,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051,8/4/2021,Antibody,C051,,,,2,E,M,N,405;417;447;449;452;453;455;456;470;472;475;476;484;485;486;487;489;490;491;492;493;494;496;498,0,1,1,0,
7R8O,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548,8/4/2021,Antibody,C548,,,,0,A,O,P,403;446;447;449;450;452;453;455;456;470;472;475;480;482;483;484;485;486;488;489;490;491;492;493;494;496;498,0,1,1,0,
7R8O,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548,8/4/2021,Antibody,C548,,,,1,B,H,L,403;446;447;449;450;452;453;455;456;470;472;475;480;482;483;484;485;486;488;489;490;491;492;493;494;496;498,0,1,1,0,
7R8O,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548,8/4/2021,Antibody,C548,,,,2,E,M,N,403;446;447;449;450;452;453;455;456;470;472;475;480;482;483;484;485;486;488;489;490;491;492;493;494;496;498,0,1,1,0,
7RA8,SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,8/4/2021,Antibody,S2X259,,,,0,A,H,L,369;370;373;374;375;376;377;378;379;380;383;384;385;386;404;405;407;408;411;412;413;416;433;435;437;502;503;504;505;508,0,1,1,0,446;447;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490
7RA8,SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,8/4/2021,Antibody,S2X259,,,,1,B,C,D,369;370;373;374;375;376;377;378;379;380;383;384;385;386;404;405;407;408;411;412;413;416;433;435;437;502;503;504;505;508,0,1,1,0,446;447;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490
7RA8,SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,8/4/2021,Antibody,S2X259,,,,2,E,F,G,369;370;373;374;375;376;377;378;379;380;383;384;385;386;404;405;407;408;411;412;413;416;433;435;437;502;503;504;505;508,0,1,1,0,446;447;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490
7RAL,SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains),8/4/2021,Antibody,S2X259,,,,0,B,H,L,369;370;372;374;375;376;377;378;379;380;383;384;385;404;405;407;408;411;412;413;414;416;433;435;437;502;503;504;506;508,0,1,1,0,446;447;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490
7RKV,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1),9/22/2021,Antibody,C118,,,,0,A,E,F,369;370;372;374;375;376;377;378;379;380;381;382;383;384;385;386;387;390;404;405;407;408;409;411;412;413;414;415;416;419;427;428;430;432;435;437;503;504;506;508,0,1,1,0,
7RKV,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1),9/22/2021,Antibody,C118,,,,1,B,D,H,369;370;371;372;375;376;377;378;379;380;381;382;383;384;385;386;387;390;404;405;407;408;409;411;412;413;414;416;419;427;428;430;432;435;437;503;504;506;508,0,1,1,0,
7RKV,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1),9/22/2021,Antibody,C118,,,,2,C,G,L,369;370;371;372;375;376;377;378;379;380;381;382;383;384;385;386;387;390;404;405;407;408;409;411;412;413;414;415;416;419;427;428;430;432;435;437;503;504;506;508,0,1,1,0,
7RR0,SARS-CoV-2 receptor binding domain bound to Fab PDI 222,10/6/2021,Antibody,PDI 222,,,,0,A,B,C,417;420;455;456;458;460;473;475;476;477;478;479;480;481;483;485;486;487;488;489;490;493,0,1,1,0,
7RW2,Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein,9/1/2021,Antibody,7-May,,,,0,A,H,L,96;99;101;103;119;121;124;126;128;151;170;172;173;174;175;176;177;178;179;180;182;187;188;190;192;203;205;207;209;224;226;227,1,0,0,0,69;70;71;72;73;74;75;246;247;248;249;250;251;252;253;254;255
7RW2,Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein,9/1/2021,Antibody,7-May,,,,1,B,G,J,96;99;101;103;119;121;124;126;128;151;170;172;173;174;175;176;177;178;179;180;182;187;188;190;192;203;205;207;209;224;226;227,1,0,0,0,69;70;71;72;73;74;75;246;247;248;249;250;251;252;253;254;255
7RW2,Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein,9/1/2021,Antibody,7-May,,,,2,C,I,K,96;99;101;103;119;121;124;126;128;151;170;172;173;174;175;176;177;178;179;180;182;187;188;190;192;203;205;207;209;224;226;227,1,0,0,0,69;70;71;72;73;74;75;246;247;248;249;250;251;252;253;254;255
7RXD,CryoEM structure of RBD domain of COVID-19 in complex with Legobody,10/6/2021,Other,Legobody,,,,0,B,H,L,405,0,1,0,0,409;410;411;412;413;414;415;416;417;418;419;420;421;422;423;424;425;426;427;428;429;430;431;432;433;434;435;436;437;438;439;440;441;442;443;444;445;446;447;448;449;450;451;452;453;454;455;456;457;458;459;460;461;462;463;464;465;466;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481
7S0B,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056,10/6/2021,Antibody,N-612-056,,,,0,E,C,D,346;348;351;352;353;354;355;356;357;359;396;398;457;459;461;462;464;465;466;467;468;469;470,0,1,1,0,
7S0B,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056,10/6/2021,Antibody,N-612-056,,,,1,F,A,B,340;346;348;351;352;353;354;355;356;357;359;396;398;457;458;459;462;464;465;466;467;468;469;470;471,0,1,1,0,
7S0C,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017,10/6/2021,Antibody,N-612-017,,,,0,A,H,L,345;346;348;349;351;352;354;444;445;446;449;450;451;452;466;468;470;482;484;490;492;493;494,0,1,1,0,519
7S0C,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017,10/6/2021,Antibody,N-612-017,,,,1,B,M,N,345;346;348;349;351;352;401;449;450;451;452;454;491;492;494,0,1,1,0,444;445;446;447;448;455;456;457;458;459;460;461;462;463;464;465;466;467;468;469;470;471;472;473;474;475;476;477;478;479;480;481;482;483;484;485;486;487;488;489;490;501;502
7S0D,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014,10/6/2021,Antibody,N-612-014,,,,0,A,M,N,27;64;66;67;68;69;77;79;80;97;98;99;100;143;145;152;185;186;187;211;212;213;214;245;247;258;260;262;263;264,1,0,0,0,71;72;73;74;75;179;180;181;182;183;184;248;249;250;251;252;253;254;255;256
7S0D,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014,10/6/2021,Antibody,N-612-014,,,,1,B,O,P,64;66;68;69;77;97;98;99;143;145;152;185;187;211;212;213;214;215;245;247;258;259;260;262;263;264,1,0,0,0,71;72;73;74;75;179;180;181;182;183;184;248;249;250;251;252;253;254;255;256
7S0D,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014,10/6/2021,Antibody,N-612-014,,,,2,C,H,L,64;66;68;69;70;77;78;95;97;98;99;100;143;145;152;185;187;211;212;213;214;245;247;258;260;262;264,1,0,0,0,71;72;73;74;75;179;180;181;182;183;184;248;249;250;251;252;253;254;255;256
7S0E,Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004,10/6/2021,Antibody,N-612-004,,,,0,A,H,L,556;557;558;560;561;562;563;564;565;566;567;568;574,0,0,0,0,517;518;519;520;521;522
7S4S,Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab,9/22/2021,Antibody,CoV11,,,,0,A,H,L,403;405;415;416;417;420;421;447;449;453;455;456;458;459;460;473;474;475;476;477;486;487;489;493;495;496;498;501;502;504;505,0,1,1,0,
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,0,A,E,D,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,1,A,C,B,23;25;26;28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;239;267;269;271;272,1,0,0,0,19;20;21;22;70;71;72;73;74;75;76;77;146;147;148;149;156;157;177;178;179;180;181;182;183;184;185;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,2,F,J,I,23;25;26;28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;239;267;269;271;272,1,0,0,0,19;20;21;22;70;71;72;73;74;75;76;77;146;147;148;149;156;157;177;178;179;180;181;182;183;184;185;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,3,F,H,G,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,4,K,O,N,23;25;26;28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;239;267;269;271;272,1,0,0,0,19;20;21;22;70;71;72;73;74;75;76;77;146;147;148;149;156;157;177;178;179;180;181;182;183;184;185;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SO9,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,Antibody,S2M11,S2L20,,,5,K,M,L,447;449;452;455;456;470;472;473;475;484;485;486;489;490;492;493;494;496;498,0,1,1,0,519
7SOA,SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement,11/17/2021,Antibody,S2L20,,,,0,A,H,L,19;23;25;26;28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;137;232;234;235;265;267;269;270,1,0,0,0,20;21;22;70;71;72;73;74;75;76;77;146;147;148;149;175;176;177;178;179;180;181;182;183;243;244;245;246;247;248;249;250;251;252;253;254;255;256;257;258;259;260
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,0,A,G,I,334;335;336;337;339;340;341;343;344;345;346;354;356;358;360;361;440;441,0,1,1,0,
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,1,A,C,B,23;25;26;28;61;63;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;267;269;271;272,1,0,0,0,19;20;21;22;68;69;70;71;72;73;74;75;76;77;78;79;145;146;147;148;149;150;151;152;178;179;180;181;182;183;184;185;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,2,D,H,J,334;335;336;337;339;340;341;343;344;345;346;354;356;358;360;361;440;441,0,1,1,0,
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,3,D,F,E,23;25;26;28;61;63;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;267;269;271;272,1,0,0,0,19;20;21;22;68;69;70;71;72;73;74;75;76;77;78;79;145;146;147;148;149;150;151;152;178;179;180;181;182;183;184;185;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,4,K,M,L,23;25;26;28;61;63;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;267;269;271;272,1,0,0,0,19;20;21;22;68;69;70;71;72;73;74;75;76;77;78;79;145;146;147;148;149;150;151;152;178;179;180;181;182;183;184;185;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7SOB,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,Antibody,S309,S2L20,,,5,K,N,O,334;335;336;337;339;340;341;343;344;345;346;354;356;358;360;361;440;441,0,1,1,0,
7SOC,SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement,11/17/2021,Antibody,S309,,,,0,A,H,L,334;335;337;339;340;341;343;344;345;346;354;356;358;361;440;441,0,1,1,0,
7SOD,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,11/17/2021,Antibody,S2L20,,,,0,A,H,L,23;25;26;28;61;63;65;82;83;84;85;87;88;108;109;110;111;113;114;137;234;236;237;267;269;271;272,1,0,0,0,19;20;21;22;68;69;70;71;72;73;74;75;76;77;78;79;145;146;147;148;149;150;151;152;178;179;180;181;182;183;184;185;247;248;249;250;251;252;253;254;255;256;257;258;259;260;261;262
7V26,XG005-bound SARS-CoV-2 S,10/20/2021,Antibody,XG005,,,,0,A,a,b,345;346;437;439;440;441;442;443;444;445;446;448;450;498;499;500;505;506;509,0,1,1,0,
7V26,XG005-bound SARS-CoV-2 S,10/20/2021,Antibody,XG005,,,,1,C,c,d,345;346;439;440;441;442;443;444;445;446;448;449;450;498;499;500;501;505;506,0,1,1,0,
7V26,XG005-bound SARS-CoV-2 S,10/20/2021,Antibody,XG005,,,,2,E,e,f,345;346;437;439;440;441;442;443;444;445;446;448;450;498;499;500;501;502;505;506,0,1,1,0,
7V2A,SARS-CoV-2 Spike trimer in complex with XG014 Fab,10/20/2021,Antibody,XG014,,,,0,A,E,D,338;339;342;343;345;346;367;368;371;373;374;434;436;437;438;439;440;441;443;444;445;450;509,0,1,1,0,476;477;478;479;480;481;482;483;484;485;499;500;501;502
7V2A,SARS-CoV-2 Spike trimer in complex with XG014 Fab,10/20/2021,Antibody,XG014,,,,1,B,G,F,338;339;342;343;345;346;367;368;371;373;374;434;436;437;438;439;440;441;443;444;445;450;509,0,1,1,0,476;477;478;479;480;481;482;483;484;485;499;500;501;502
7V2A,SARS-CoV-2 Spike trimer in complex with XG014 Fab,10/20/2021,Antibody,XG014,,,,2,C,I,H,338;339;342;343;345;346;367;368;371;373;374;436;437;438;439;440;441;443;444;445;450;509,0,1,1,0,476;477;478;479;480;481;482;483;484;485;499;500;501;502
7VMU,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,11/3/2021,Antibody,E4,,,,0,B,A,a,415;416;417;420;421;453;455;456;458;459;460;473;474;475;476;477;486;487;489;490;491;493;496,0,1,1,0,390;391;392;393;394
